drug	genes	question	answer
abacavir	HLA-B	What would be the clinical guidance for someone who is HLA-B*57:01 negative for HLA-B with regards to taking abacavir?	Use abacavir per standard dosing guidelines
abacavir	HLA-B	What would be the clinical guidance for someone who is HLA-B*57:01 positive for HLA-B with regards to taking abacavir?	Abacavir is not recommended
allopurinol	HLA-B	What would be the clinical guidance for someone who is HLA-B*58:01 negative for HLA-B with regards to taking allopurinol?	Use allopurinol per standard dosing guidelines
allopurinol	HLA-B	What would be the clinical guidance for someone who is HLA-B*58:01 positive for HLA-B with regards to taking allopurinol?	Allopurinol is contraindicated
amikacin	MT-RNR1	What would be the clinical guidance for someone who is increased risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking amikacin?	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.
amikacin	MT-RNR1	What would be the clinical guidance for someone who is normal risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking amikacin?	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.
amikacin	MT-RNR1	What would be the clinical guidance for someone who is uncertain risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking amikacin?	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.
gentamicin	MT-RNR1	What would be the clinical guidance for someone who is increased risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking gentamicin?	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.
gentamicin	MT-RNR1	What would be the clinical guidance for someone who is normal risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking gentamicin?	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.
gentamicin	MT-RNR1	What would be the clinical guidance for someone who is uncertain risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking gentamicin?	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.
kanamycin	MT-RNR1	What would be the clinical guidance for someone who is increased risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking kanamycin?	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.
kanamycin	MT-RNR1	What would be the clinical guidance for someone who is normal risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking kanamycin?	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.
kanamycin	MT-RNR1	What would be the clinical guidance for someone who is uncertain risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking kanamycin?	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.
paromomycin	MT-RNR1	What would be the clinical guidance for someone who is increased risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking paromomycin?	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.
paromomycin	MT-RNR1	What would be the clinical guidance for someone who is normal risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking paromomycin?	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.
paromomycin	MT-RNR1	What would be the clinical guidance for someone who is uncertain risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking paromomycin?	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.
plazomicin	MT-RNR1	What would be the clinical guidance for someone who is increased risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking plazomicin?	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.
plazomicin	MT-RNR1	What would be the clinical guidance for someone who is normal risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking plazomicin?	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.
plazomicin	MT-RNR1	What would be the clinical guidance for someone who is uncertain risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking plazomicin?	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.
streptomycin	MT-RNR1	What would be the clinical guidance for someone who is increased risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking streptomycin?	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.
streptomycin	MT-RNR1	What would be the clinical guidance for someone who is normal risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking streptomycin?	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.
streptomycin	MT-RNR1	What would be the clinical guidance for someone who is uncertain risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking streptomycin?	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.
tobramycin	MT-RNR1	What would be the clinical guidance for someone who is increased risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking tobramycin?	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.
vitamin c	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking vitamin c?	No reason to avoid based on G6PD status
tobramycin	MT-RNR1	What would be the clinical guidance for someone who is normal risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking tobramycin?	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.
tobramycin	MT-RNR1	What would be the clinical guidance for someone who is uncertain risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking tobramycin?	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.
dibekacin	MT-RNR1	What would be the clinical guidance for someone who is increased risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking dibekacin?	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.
dibekacin	MT-RNR1	What would be the clinical guidance for someone who is normal risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking dibekacin?	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.
dibekacin	MT-RNR1	What would be the clinical guidance for someone who is uncertain risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking dibekacin?	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.
neomycin	MT-RNR1	What would be the clinical guidance for someone who is increased risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking neomycin?	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.
neomycin	MT-RNR1	What would be the clinical guidance for someone who is normal risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking neomycin?	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.
neomycin	MT-RNR1	What would be the clinical guidance for someone who is uncertain risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking neomycin?	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.
netilmicin	MT-RNR1	What would be the clinical guidance for someone who is increased risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking netilmicin?	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.
netilmicin	MT-RNR1	What would be the clinical guidance for someone who is normal risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking netilmicin?	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.
dimercaprol	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking dimercaprol?	No reason to avoid based on G6PD status at standard doses
netilmicin	MT-RNR1	What would be the clinical guidance for someone who is uncertain risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking netilmicin?	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.
ribostamycin	MT-RNR1	What would be the clinical guidance for someone who is increased risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking ribostamycin?	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.
ribostamycin	MT-RNR1	What would be the clinical guidance for someone who is normal risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking ribostamycin?	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.
ribostamycin	MT-RNR1	What would be the clinical guidance for someone who is uncertain risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking ribostamycin?	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.
aminosalicylic acid	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking aminosalicylic acid?	No reason to avoid based on G6PD status
aminosalicylic acid	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking aminosalicylic acid?	No reason to avoid based on G6PD status at standard doses
aminosalicylic acid	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking aminosalicylic acid?	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended
aminosalicylic acid	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking aminosalicylic acid?	No reason to avoid based on G6PD status at standard doses
aminosalicylic acid	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking aminosalicylic acid?	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.
ciprofloxacin	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking ciprofloxacin?	No reason to avoid based on G6PD status
ciprofloxacin	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking ciprofloxacin?	No reason to avoid based on G6PD status at standard doses
ciprofloxacin	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking ciprofloxacin?	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended
ciprofloxacin	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking ciprofloxacin?	No reason to avoid based on G6PD status at standard doses
ciprofloxacin	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking ciprofloxacin?	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.
dimercaprol	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking dimercaprol?	No reason to avoid based on G6PD status
mafenide	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking mafenide?	No reason to avoid based on G6PD status
dimercaprol	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking dimercaprol?	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended
dimercaprol	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking dimercaprol?	No reason to avoid based on G6PD status at standard doses
dimercaprol	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking dimercaprol?	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.
doxorubicin	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking doxorubicin?	No reason to avoid based on G6PD status
doxorubicin	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking doxorubicin?	No reason to avoid based on G6PD status at standard doses
doxorubicin	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking doxorubicin?	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended
doxorubicin	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking doxorubicin?	No reason to avoid based on G6PD status at standard doses
doxorubicin	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking doxorubicin?	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.
furazolidone	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking furazolidone?	No reason to avoid based on G6PD status
furazolidone	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking furazolidone?	No reason to avoid based on G6PD status at standard doses
furazolidone	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking furazolidone?	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended
furazolidone	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking furazolidone?	No reason to avoid based on G6PD status at standard doses
furazolidone	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking furazolidone?	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.
glyburide	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking glyburide?	No reason to avoid based on G6PD status
glyburide	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking glyburide?	No reason to avoid based on G6PD status at standard doses
glyburide	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking glyburide?	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended
glyburide	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking glyburide?	No reason to avoid based on G6PD status at standard doses
glyburide	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking glyburide?	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.
mafenide	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking mafenide?	No reason to avoid based on G6PD status at standard doses
mafenide	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking mafenide?	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended
mafenide	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking mafenide?	No reason to avoid based on G6PD status at standard doses
mafenide	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking mafenide?	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.
nalidixic acid	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking nalidixic acid?	No reason to avoid based on G6PD status
nalidixic acid	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking nalidixic acid?	No reason to avoid based on G6PD status at standard doses
nalidixic acid	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking nalidixic acid?	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended
nalidixic acid	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking nalidixic acid?	No reason to avoid based on G6PD status at standard doses
nalidixic acid	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking nalidixic acid?	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.
norfloxacin	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking norfloxacin?	No reason to avoid based on G6PD status
norfloxacin	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking norfloxacin?	No reason to avoid based on G6PD status at standard doses
norfloxacin	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking norfloxacin?	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended
norfloxacin	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking norfloxacin?	No reason to avoid based on G6PD status at standard doses
norfloxacin	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking norfloxacin?	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.
ofloxacin	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking ofloxacin?	No reason to avoid based on G6PD status
ofloxacin	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking ofloxacin?	No reason to avoid based on G6PD status at standard doses
ofloxacin	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking ofloxacin?	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended
vitamin c	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking vitamin c?	No reason to avoid based on G6PD status at standard doses
ofloxacin	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking ofloxacin?	No reason to avoid based on G6PD status at standard doses
ofloxacin	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking ofloxacin?	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	Initiate therapy with recommended starting dose.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	Initiate therapy with recommended starting dose.
quinine	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking quinine?	No reason to avoid based on G6PD status
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	Initiate therapy with recommended starting dose.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	Initiate therapy with recommended starting dose.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	Initiate therapy with recommended starting dose.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use. If a amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	No recommendation
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	Initiate therapy with recommended starting dose.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking amitriptyline?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking amitriptyline?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking amitriptyline?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking amitriptyline?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking amitriptyline?	Initiate therapy with recommended starting dose.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking amitriptyline?	Initiate therapy with recommended starting dose.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking amitriptyline?	Initiate therapy with recommended starting dose.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking amitriptyline?	Initiate therapy with recommended starting dose.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking amitriptyline?	Initiate therapy with recommended starting dose.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use. If a amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking amitriptyline?	No recommendation
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking amitriptyline?	Initiate therapy with recommended starting dose.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking amitriptyline?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use. If amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use. If amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use. If amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use. If amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use. If amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is No Result for TPMT and Indeterminate for NUDT15 with regards to taking azathioprine?	NUDT15 phenotype could not be assigned based on genotyping performed and no TPMT genotype is available. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking amitriptyline?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking amitriptyline?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.
tamoxifen	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 with regards to taking tamoxifen?	Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	Initiate therapy with recommended starting dose.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.
chloramphenicol	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking chloramphenicol?	No reason to avoid based on G6PD status at standard doses
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking amitriptyline?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking amitriptyline?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking amitriptyline?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking amitriptyline?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking amitriptyline?	No recommendation
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking amitriptyline?	No recommendation
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking amitriptyline?	No recommendation
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking amitriptyline?	No recommendation
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking amitriptyline?	No recommendation
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking amitriptyline?	Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
chloramphenicol	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking chloramphenicol?	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking amitriptyline?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking amitriptyline?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking amitriptyline?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking amitriptyline?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking amitriptyline?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking amitriptyline?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking amitriptyline?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking amitriptyline?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and Indeterminate for CYP2C19 with regards to taking amitriptyline?	No recommendation
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Indeterminate for CYP2C19 with regards to taking amitriptyline?	No recommendation
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	Initiate therapy with recommended starting dose.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	Initiate therapy with recommended starting dose.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	Initiate therapy with recommended starting dose.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	Initiate therapy with recommended starting dose.
chloroquine	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking chloroquine?	No reason to avoid based on G6PD status at standard doses
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use. If a amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
atazanavir	UGT1A1	What would be the clinical guidance for someone who is Indeterminate for UGT1A1 with regards to taking atazanavir?	No recommendation
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	No recommendation
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline?	Initiate therapy with recommended starting dose.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
tramadol	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 with regards to taking tramadol?	Use tramadol label recommended age- or weight-specific dosing.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use. If amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use. If amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is Indeterminate for TPMT and No Result for NUDT15 with regards to taking azathioprine?	TPMT phenotype could not be assigned based on genotyping performed and NUDT15 genotype is not available. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use. If amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use. If amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use. If amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
tamoxifen	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 with regards to taking tamoxifen?	Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking amitriptyline?	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and No Result for CYP2C19 with regards to taking amitriptyline?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and No Result for CYP2C19 with regards to taking amitriptyline?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and No Result for CYP2C19 with regards to taking amitriptyline?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and No Result for CYP2C19 with regards to taking amitriptyline?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and No Result for CYP2C19 with regards to taking amitriptyline?	Initiate therapy with recommended starting dose.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and No Result for CYP2C19 with regards to taking amitriptyline?	Initiate therapy with recommended starting dose.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and No Result for CYP2C19 with regards to taking amitriptyline?	Initiate therapy with recommended starting dose.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and No Result for CYP2C19 with regards to taking amitriptyline?	Initiate therapy with recommended starting dose.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and No Result for CYP2C19 with regards to taking amitriptyline?	Initiate therapy with recommended starting dose.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and No Result for CYP2C19 with regards to taking amitriptyline?	Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
chloroquine	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking chloroquine?	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and No Result for CYP2C19 with regards to taking amitriptyline?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and No Result for CYP2C19 with regards to taking amitriptyline?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and No Result for CYP2C19 with regards to taking amitriptyline?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and No Result for CYP2C19 with regards to taking amitriptyline?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and No Result for CYP2C19 with regards to taking amitriptyline?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and No Result for CYP2C19 with regards to taking amitriptyline?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and No Result for CYP2C19 with regards to taking amitriptyline?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and No Result for CYP2C19 with regards to taking amitriptyline?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and No Result for CYP2C19 with regards to taking amitriptyline?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
chloroquine	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking chloroquine?	No reason to avoid based on G6PD status at standard doses
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and No Result for CYP2C19 with regards to taking amitriptyline?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and No Result for CYP2C19 with regards to taking amitriptyline?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and No Result for CYP2C19 with regards to taking amitriptyline?	No recommendation
aspirin	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking aspirin?	No reason to avoid based on G6PD status
aspirin	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking aspirin?	No reason to avoid based on G6PD status at standard doses
aspirin	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking aspirin?	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended
aspirin	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking aspirin?	No reason to avoid based on G6PD status at standard doses
aspirin	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking aspirin?	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.
atazanavir	UGT1A1	What would be the clinical guidance for someone who is Normal Metabolizer for UGT1A1 with regards to taking atazanavir?	There is no need to avoid prescribing of atazanavir based on UGT1A1 genetic test result. Inform the patient that some patients stop atazanavir because of jaundice (yellow eyes and skin), but that this patient's genotype makes this unlikely (less than about a 1 in 20 chance of stopping atazanavir because of jaundice).
atazanavir	UGT1A1	What would be the clinical guidance for someone who is Intermediate Metabolizer for UGT1A1 with regards to taking atazanavir?	There is no need to avoid prescribing of atazanavir based on UGT1A1 genetic test result. Inform the patient that some patients stop atazanavir because of jaundice (yellow eyes and skin), but that this patient's genotype makes this unlikely (less than about a 1 in 20 chance of stopping atazanavir because of jaundice).
atazanavir	UGT1A1	What would be the clinical guidance for someone who is Poor Metabolizer for UGT1A1 with regards to taking atazanavir?	Consider an alternative agent particularly where jaundice would be of concern to the patient. If atazanavir is to be prescribed, there is a high likelihood of developing jaundice that will result in atazanavir discontinuation (at least 20% and as high as 60%).
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 with regards to taking atomoxetine?	Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 with regards to taking atomoxetine?	Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 with regards to taking atomoxetine?	Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 with regards to taking atomoxetine?	Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 with regards to taking atomoxetine?	Initiate with a dose of 0.5 mg/kg and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If < 200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 with regards to taking atomoxetine?	Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 with regards to taking atomoxetine?	Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 with regards to taking atomoxetine?	Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 with regards to taking atomoxetine?	Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 with regards to taking atomoxetine?	Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 with regards to taking atomoxetine?	Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 with regards to taking atomoxetine?	Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If < 200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 with regards to taking atomoxetine?	Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If < 200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 with regards to taking atomoxetine?	Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If < 200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 with regards to taking atomoxetine?	Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If < 200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 with regards to taking atomoxetine?	Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If < 200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 with regards to taking atomoxetine?	Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If < 200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 with regards to taking atomoxetine?	Initiate with a dose of 0.5 mg/kg/day and if no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a plasma concentration 2 to 4 hours after dosing. If response is inadequate and concentration is < 200 ng/mL, consider a proportional dose increase to achieve a concentration to approach 400 ng/mL. If unacceptable side effects are present at any time, consider a reduction in dose.
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 with regards to taking atomoxetine?	Initiate with a dose of 0.5 mg/kg/day and if no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a plasma concentration 2 to 4 hours after dosing. If response is inadequate and concentration is < 200 ng/mL, consider a proportional dose increase to achieve a concentration to approach 400 ng/mL. If unacceptable side effects are present at any time, consider a reduction in dose.
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 with regards to taking atomoxetine?	Initiate with a dose of 0.5 mg/kg/day and if no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a plasma concentration 2 to 4 hours after dosing. If response is inadequate and concentration is < 200 ng/mL, consider a proportional dose increase to achieve a concentration to approach 400 ng/mL. If unacceptable side effects are present at any time, consider a reduction in dose.
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 with regards to taking atomoxetine?	Initiate with a dose of 0.5 mg/kg/day and if no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a plasma concentration 4 hours after dosing. If response is inadequate and concentration is < 200 ng/mL, consider a proportional dose increase to achieve a concentration to approach 400 ng/mL. If unacceptable side effects are present at any time, consider a reduction in dose.
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 with regards to taking atomoxetine?	No recommendation
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 with regards to taking atomoxetine?	Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 with regards to taking atomoxetine?	Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.
tamoxifen	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 with regards to taking tamoxifen?	Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 with regards to taking atomoxetine?	Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 with regards to taking atomoxetine?	Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 with regards to taking atomoxetine?	Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 with regards to taking atomoxetine?	Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 with regards to taking atomoxetine?	Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.
chloroquine	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking chloroquine?	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 with regards to taking atomoxetine?	Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 with regards to taking atomoxetine?	Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 with regards to taking atomoxetine?	Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 with regards to taking atomoxetine?	Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 with regards to taking atomoxetine?	Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.
hydroxychloroquine	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking hydroxychloroquine?	No reason to avoid based on G6PD status at standard doses
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 with regards to taking atomoxetine?	Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 with regards to taking atomoxetine?	Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 with regards to taking atomoxetine?	Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 with regards to taking atomoxetine?	Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 with regards to taking atomoxetine?	Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.
fluvoxamine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 with regards to taking fluvoxamine?	Initiate therapy with recommended starting dose.
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 with regards to taking atomoxetine?	Initiate with a dose of 40 mg/day and if no clinical response and in the absence of adverse events after 2 weeks increase dose to 80 mg/day. If response is inadequate after 2 weeks consider obtaining a plasma concentration 2-4 h after dosing. If concentration is <200 ng/mL, consider a proportional dose increase to achieve a concentration to approach 400 ng/mL. If unacceptable side effects are present at any time, consider a reduction in dose.
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 with regards to taking atomoxetine?	Initiate with a dose of 40 mg/day and if no clinical response and in the absence of adverse events after 2 weeks increase dose to 80 mg/day. If response is inadequate after 2 weeks consider obtaining a plasma concentration 2-4 h after dosing. If concentration is <200 ng/mL, consider a proportional dose increase to achieve a concentration to approach 400 ng/mL. If unacceptable side effects are present at any time, consider a reduction in dose.
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 with regards to taking atomoxetine?	Initiate with a dose of 40 mg/day and if no clinical response and in the absence of adverse events after 2 weeks increase dose to 80 mg/day. If response is inadequate after 2 weeks consider obtaining a plasma concentration 2-4 h after dosing. If concentration is <200 ng/mL, consider a proportional dose increase to achieve a concentration to approach 400 ng/mL. If unacceptable side effects are present at any time, consider a reduction in dose.
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 with regards to taking atomoxetine?	Initiate with a dose of 40 mg/day and if no clinical response and in the absence of adverse events after 2 weeks increase dose to 80 mg/day. If response is inadequate after 2 weeks, consider obtaining a plasma concentration 2 to 4 hours after dosing. If concentration is <200 ng/mL, consider a proportional dose increase to achieve a concentration to approach 400 ng/mL. If unacceptable side effects are present at any time, consider a reduction in dose.
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 with regards to taking atomoxetine?	No recommendation
atorvastatin	SLCO1B1	What would be the clinical guidance for someone who is Increased Function for SLCO1B1 with regards to taking atorvastatin?	Prescribe desired starting dose and adjust doses based on disease-specific guidelines.
atorvastatin	SLCO1B1	What would be the clinical guidance for someone who is Normal Function for SLCO1B1 with regards to taking atorvastatin?	Prescribe desired starting dose and adjust doses based on disease-specific guidelines.
atorvastatin	SLCO1B1	What would be the clinical guidance for someone who is Possible Decreased Function for SLCO1B1 with regards to taking atorvastatin?	Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for 40mg dose. If dose >40mg needed for desired efficacy, consider combination therapy (i.e., atorvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
atorvastatin	SLCO1B1	What would be the clinical guidance for someone who is Decreased Function for SLCO1B1 with regards to taking atorvastatin?	Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for 40mg dose. If dose >40mg needed for desired efficacy, consider combination therapy (i.e., atorvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
atorvastatin	SLCO1B1	What would be the clinical guidance for someone who is Poor Function for SLCO1B1 with regards to taking atorvastatin?	Prescribe ≤20mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If dose >20mg is needed for desired efficacy, consider rosuvastatin or combination therapy (i.e., atorvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
atorvastatin	SLCO1B1	What would be the clinical guidance for someone who is Indeterminate for SLCO1B1 with regards to taking atorvastatin?	No recommendation
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is Indeterminate for TPMT and Indeterminate for NUDT15 with regards to taking azathioprine?	Neither TPMT or NUDT15 phenotype could be assigned based on genotyping performed. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is Indeterminate for TPMT and Intermediate Metabolizer for NUDT15 with regards to taking azathioprine?	Based on NUDT15 status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532). TPMT phenotype could not be assigned based on genotyping performed. Consider evaluating erythrocyte TPMT activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is Indeterminate for TPMT and Normal Metabolizer for NUDT15 with regards to taking azathioprine?	Based on NUDT15, start with normal starting dose (e.g., 2-3 mg/kg/day) and adjust doses of azathioprine based on disease-specific guidelines. Allow 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506). TPMT phenotype could not be assigned based on genotyping performed. Consider evaluating erythrocyte TPMT activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is Indeterminate for TPMT and Poor Metabolizer for NUDT15 with regards to taking azathioprine?	Based on NUDT15 status, for non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignant conditions, start with drastically reduced normal daily doses (reduce daily dose by 10-fold) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment (PMID 16530578, 11302950, 15606506, 16530532, 12477776). TPMT phenotype could not be assigned based on genotyping performed. Consider evaluating erythrocyte TPMT activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is Indeterminate for TPMT and Possible Intermediate Metabolizer for NUDT15 with regards to taking azathioprine?	Based on NUDT15 status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532). TPMT phenotype could not be assigned based on genotyping performed. Consider evaluating erythrocyte TPMT activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is No Result for TPMT and Intermediate Metabolizer for NUDT15 with regards to taking azathioprine?	Based on NUDT15 status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532). TPMT genotype is not available. Consider evaluating erythrocyte TPMT activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is No Result for TPMT and Normal Metabolizer for NUDT15 with regards to taking azathioprine?	Based on NUDT15, start with normal starting dose (e.g., 2-3 mg/kg/day) and adjust doses of azathioprine based on disease-specific guidelines. Allow 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506). TPMT genotype is not available. Consider evaluating erythrocyte TPMT activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is No Result for TPMT and Poor Metabolizer for NUDT15 with regards to taking azathioprine?	Based on NUDT15 status, for non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignant conditions, start with drastically reduced normal daily doses (reduce daily dose by 10-fold) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment (PMID 16530578, 11302950, 15606506, 16530532, 12477776). TPMT genotype is not available. Consider evaluating erythrocyte TPMT activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is No Result for TPMT and Possible Intermediate Metabolizer for NUDT15 with regards to taking azathioprine?	Based on NUDT15 status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532). TPMT genotype is not available. Consider evaluating erythrocyte TPMT activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is Possible Intermediate Metabolizer for TPMT and Indeterminate for NUDT15 with regards to taking azathioprine?	Based on TPMT status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532). NUDT15 phenotype could not be assigned based on genotyping. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is Possible Intermediate Metabolizer for TPMT and Intermediate Metabolizer for NUDT15 with regards to taking azathioprine?	Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532).
hydroxychloroquine	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking hydroxychloroquine?	No reason to avoid based on G6PD status at standard doses
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is Possible Intermediate Metabolizer for TPMT and Normal Metabolizer for NUDT15 with regards to taking azathioprine?	Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532).
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is Possible Intermediate Metabolizer for TPMT and Poor Metabolizer for NUDT15 with regards to taking azathioprine?	For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignant conditions, start with drastically reduced normal daily doses (reduce daily dose by 10-fold) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment (PMID 16530578, 11302950, 15606506, 16530532, 12477776).
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is Possible Intermediate Metabolizer for TPMT and Possible Intermediate Metabolizer for NUDT15 with regards to taking azathioprine?	Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532).
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is Possible Intermediate Metabolizer for TPMT and No Result for NUDT15 with regards to taking azathioprine?	Based on TPMT status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532). NUDT15 genotype is not available. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is Intermediate Metabolizer for TPMT and Indeterminate for NUDT15 with regards to taking azathioprine?	Based on TPMT status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532). NUDT15 phenotype could not be assigned based on genotyping. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity.
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is Intermediate Metabolizer for TPMT and Intermediate Metabolizer for NUDT15 with regards to taking azathioprine?	Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532).
carbamazepine	HLA-A;HLA-B	What would be the clinical guidance for someone who is HLA-A*31:01 negative for HLA-A and No HLA-B Result for HLA-B with regards to taking carbamazepine?	Use carbamazepine per standard dosing guidelines.
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is Intermediate Metabolizer for TPMT and Normal Metabolizer for NUDT15 with regards to taking azathioprine?	Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532).
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is Intermediate Metabolizer for TPMT and Poor Metabolizer for NUDT15 with regards to taking azathioprine?	For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignant conditions, start with drastically reduced normal daily doses (reduce daily dose by 10-fold) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment (PMID 16530578, 11302950, 15606506, 16530532, 12477776).
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is Intermediate Metabolizer for TPMT and Possible Intermediate Metabolizer for NUDT15 with regards to taking azathioprine?	Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532).
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is Intermediate Metabolizer for TPMT and No Result for NUDT15 with regards to taking azathioprine?	Based on TPMT status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532). NUDT15 genotype is not available. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity.
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is Normal Metabolizer for TPMT and Indeterminate for NUDT15 with regards to taking azathioprine?	Based on TPMT status, start with normal starting dose (e.g., 2-3 mg/kg/day) and adjust doses of azathioprine based on disease-specific guidelines. Allow 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506). NUDT15 status could not be determined based on genotyping. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity.
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is Normal Metabolizer for TPMT and Intermediate Metabolizer for NUDT15 with regards to taking azathioprine?	Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532).
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is Normal Metabolizer for TPMT and Normal Metabolizer for NUDT15 with regards to taking azathioprine?	Start with normal starting dose (e.g., 2-3 mg/kg/day) and adjust doses of azathioprine based on disease-specific guidelines. Allow 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506).
hydroxychloroquine	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking hydroxychloroquine?	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is Normal Metabolizer for TPMT and Poor Metabolizer for NUDT15 with regards to taking azathioprine?	For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignant conditions, start with drastically reduced normal daily doses (reduce daily dose by 10-fold) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment (PMID 16530578, 11302950, 15606506, 16530532, 12477776).
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is Normal Metabolizer for TPMT and Possible Intermediate Metabolizer for NUDT15 with regards to taking azathioprine?	Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532).
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is Normal Metabolizer for TPMT and No Result for NUDT15 with regards to taking azathioprine?	Based on TPMT status, start with normal starting dose (e.g., 2-3 mg/kg/day) and adjust doses of azathioprine based on disease-specific guidelines. Allow 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506). NUDT15 genotype is not available. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity.
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is Poor Metabolizer for TPMT and Indeterminate for NUDT15 with regards to taking azathioprine?	Based on TPMT status, for non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignancy, start with drastically reduced doses (reduce daily dose by 10-fold and dose thrice weekly instead of daily) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment (PMID 16530578, 11302950, 15606506, 16530532, 12477776). NUDT15 status could not be determined based on genotyping. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity.
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is Poor Metabolizer for TPMT and Intermediate Metabolizer for NUDT15 with regards to taking azathioprine?	For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignancy, start with drastically reduced doses (reduce daily dose by 10-fold and dose thrice weekly instead of daily) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment (PMID 16530578, 11302950, 15606506, 16530532, 12477776).
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is Poor Metabolizer for TPMT and Normal Metabolizer for NUDT15 with regards to taking azathioprine?	For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignancy, start with drastically reduced doses (reduce daily dose by 10-fold and dose thrice weekly instead of daily) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment (PMID 16530578, 11302950, 15606506, 16530532, 12477776).
carbamazepine	HLA-A;HLA-B	What would be the clinical guidance for someone who is No HLA-A Result for HLA-A and HLA-B*15:02 positive for HLA-B with regards to taking carbamazepine?	If patient is carbamazepine-naïve, do not use carbamazepine.
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is Poor Metabolizer for TPMT and Poor Metabolizer for NUDT15 with regards to taking azathioprine?	For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignancy, start with drastically reduced doses (reduce daily dose by 10-fold and dose thrice weekly instead of daily) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment (PMID 16530578, 11302950, 15606506, 16530532, 12477776).
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is Poor Metabolizer for TPMT and Possible Intermediate Metabolizer for NUDT15 with regards to taking azathioprine?	For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignancy, start with drastically reduced doses (reduce daily dose by 10-fold and dose thrice weekly instead of daily) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment (PMID 16530578, 11302950, 15606506, 16530532, 12477776).
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is Poor Metabolizer for TPMT and No Result for NUDT15 with regards to taking azathioprine?	Based on TPMT status, for non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignancy, start with drastically reduced doses (reduce daily dose by 10-fold and dose thrice weekly instead of daily) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment (PMID 16530578, 11302950, 15606506, 16530532, 12477776). NUDT15 genotype is not available. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity.
carbamazepine	HLA-A;HLA-B	What would be the clinical guidance for someone who is HLA-A*31:01 positive for HLA-A and HLA-B*15:02 negative for HLA-B with regards to taking carbamazepine?	If patient is carbamazepine-naïve and alternative agents are available, do not use carbamazepine.
carbamazepine	HLA-A;HLA-B	What would be the clinical guidance for someone who is No HLA-A Result for HLA-A and HLA-B*15:02 negative for HLA-B with regards to taking carbamazepine?	Use carbamazepine per standard dosing guidelines.
carbamazepine	HLA-A;HLA-B	What would be the clinical guidance for someone who is HLA-A*31:01 negative for HLA-A and HLA-B*15:02 positive for HLA-B with regards to taking carbamazepine?	If patient is carbamazepine-naïve, do not use carbamazepine.
carbamazepine	HLA-A;HLA-B	What would be the clinical guidance for someone who is HLA-A*31:01 positive for HLA-A and HLA-B*15:02 positive for HLA-B with regards to taking carbamazepine?	If patient is carbamazepine-naïve, do not use carbamazepine.
carbamazepine	HLA-A;HLA-B	What would be the clinical guidance for someone who is HLA-A*31:01 positive for HLA-A and No HLA-B Result for HLA-B with regards to taking carbamazepine?	If patient is carbamazepine-naïve and alternative agents are available, do not use carbamazepine.
carbamazepine	HLA-A;HLA-B	What would be the clinical guidance for someone who is HLA-A*31:01 negative for HLA-A and HLA-B*15:02 negative for HLA-B with regards to taking carbamazepine?	Use carbamazepine per standard dosing guidelines.
carbamazepine	HLA-A;HLA-B	What would be the clinical guidance for someone who is HLA-A*31:01 negative for HLA-A and HLA-B*15:02 negative for HLA-B with regards to taking carbamazepine?	Use carbamazepine per standard dosing guidelines.
carbamazepine	HLA-A;HLA-B	What would be the clinical guidance for someone who is HLA-A*31:01 positive for HLA-A and HLA-B*15:02 negative for HLA-B with regards to taking carbamazepine?	If patient is carbamazepine-naïve and alternative agents are not available, consider the use of carbamazepine with increased frequency of clinical monitoring. Discontinue therapy at first evidence of a cutaneous adverse reaction.
carbamazepine	HLA-A;HLA-B	What would be the clinical guidance for someone who is No HLA-A Result for HLA-A and HLA-B*15:02 negative for HLA-B with regards to taking carbamazepine?	Use carbamazepine per standard dosing guidelines.
carbamazepine	HLA-A;HLA-B	What would be the clinical guidance for someone who is HLA-A*31:01 negative for HLA-A and HLA-B*15:02 positive for HLA-B with regards to taking carbamazepine?	If patient is carbamazepine-naïve, do not use carbamazepine.
carbamazepine	HLA-A;HLA-B	What would be the clinical guidance for someone who is HLA-A*31:01 positive for HLA-A and HLA-B*15:02 positive for HLA-B with regards to taking carbamazepine?	If patient is carbamazepine-naïve, do not use carbamazepine.
carbamazepine	HLA-A;HLA-B	What would be the clinical guidance for someone who is No HLA-A Result for HLA-A and HLA-B*15:02 positive for HLA-B with regards to taking carbamazepine?	If patient is carbamazepine-naïve, do not use carbamazepine.
carbamazepine	HLA-A;HLA-B	What would be the clinical guidance for someone who is HLA-A*31:01 negative for HLA-A and No HLA-B Result for HLA-B with regards to taking carbamazepine?	Use carbamazepine per standard dosing guidelines.
carbamazepine	HLA-A;HLA-B	What would be the clinical guidance for someone who is HLA-A*31:01 positive for HLA-A and No HLA-B Result for HLA-B with regards to taking carbamazepine?	If patient is carbamazepine-naïve and alternative agents are not available, consider the use of carbamazepine with increased frequency of clinical monitoring. Discontinue therapy at first evidence of a cutaneous adverse reaction.
carbamazepine	HLA-A;HLA-B	What would be the clinical guidance for someone who is HLA-A*31:01 negative for HLA-A and HLA-B*15:02 negative for HLA-B with regards to taking carbamazepine?	Use carbamazepine per standard dosing guidelines.
carbamazepine	HLA-A;HLA-B	What would be the clinical guidance for someone who is HLA-A*31:01 positive for HLA-A and HLA-B*15:02 negative for HLA-B with regards to taking carbamazepine?	The latency period for cutaneous adverse drug reactions is variable depending on phenotype; however, all usually occur within three months of regular dosing. Therefore, if the patient has previously used carbamazepine consistently for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of carbamazepine.
carbamazepine	HLA-A;HLA-B	What would be the clinical guidance for someone who is No HLA-A Result for HLA-A and HLA-B*15:02 negative for HLA-B with regards to taking carbamazepine?	Use carbamazepine per standard dosing guidelines.
carbamazepine	HLA-A;HLA-B	What would be the clinical guidance for someone who is HLA-A*31:01 negative for HLA-A and HLA-B*15:02 positive for HLA-B with regards to taking carbamazepine?	The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (~4-28 days), and cases usually occur within three months of dosing; therefore, if the patient has previously used carbamazepine consistently for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of carbamazepine in the future.
carbamazepine	HLA-A;HLA-B	What would be the clinical guidance for someone who is HLA-A*31:01 positive for HLA-A and HLA-B*15:02 positive for HLA-B with regards to taking carbamazepine?	The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (~4-28 days), and cases usually occur within three months of dosing; therefore, if the patient has previously used carbamazepine consistently for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of carbamazepine in the future.
flurbiprofen	CYP2C9	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2C9 with regards to taking flurbiprofen?	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.
hydroxychloroquine	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking hydroxychloroquine?	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended
carbamazepine	HLA-A;HLA-B	What would be the clinical guidance for someone who is No HLA-A Result for HLA-A and HLA-B*15:02 positive for HLA-B with regards to taking carbamazepine?	The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (~4-28 days), and cases usually occur within three months of dosing; therefore, if the patient has previously used carbamazepine consistently for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of carbamazepine in the future.
carbamazepine	HLA-A;HLA-B	What would be the clinical guidance for someone who is HLA-A*31:01 negative for HLA-A and No HLA-B Result for HLA-B with regards to taking carbamazepine?	Use carbamazepine per standard dosing guidelines.
carbamazepine	HLA-A;HLA-B	What would be the clinical guidance for someone who is HLA-A*31:01 positive for HLA-A and No HLA-B Result for HLA-B with regards to taking carbamazepine?	The latency period for cutaneous adverse drug reactions is variable depending on phenotype; however, all usually occur within three months of regular dosing. Therefore, if the patient has previously used carbamazepine consistently for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of carbamazepine.
celecoxib	CYP2C9	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2C9 with regards to taking celecoxib?	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.
celecoxib	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.5 for CYP2C9 with regards to taking celecoxib?	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.
celecoxib	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2C9 with regards to taking celecoxib?	Initiate therapy with lowest recommended starting dose. Titrate dose upward to clinical effect or maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Carefully monitor adverse events such as blood pressure and kidney function during course of therapy.
celecoxib	CYP2C9	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.5 for CYP2C9 with regards to taking celecoxib?	Initiate therapy with 25-50% of the lowest recommended starting dose. Titrate dose upward to clinical effect or 25-50% of the maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Upward dose titration should not occur until after steady state is reached (at least 8 days for celecoxib after first dose in PMs). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider an alternate therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo.
celecoxib	CYP2C9	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2C9 with regards to taking celecoxib?	Initiate therapy with 25-50% of the lowest recommended starting dose. Titrate dose upward to clinical effect or 25-50% of the maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Upward dose titration should not occur until after steady state is reached (at least 8 days for celecoxib after first dose in PMs). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider an alternate therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo.
celecoxib	CYP2C9	What would be the clinical guidance for someone who is Indeterminate for CYP2C9 with regards to taking celecoxib?	No recommendation
flurbiprofen	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.5 for CYP2C9 with regards to taking flurbiprofen?	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.
flurbiprofen	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2C9 with regards to taking flurbiprofen?	Initiate therapy with lowest recommended starting dose. Titrate dose upward to clinical effect or maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Carefully monitor adverse events such as blood pressure and kidney function during course of therapy.
flurbiprofen	CYP2C9	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.5 for CYP2C9 with regards to taking flurbiprofen?	Initiate therapy with 25-50% of the lowest recommended starting dose. Titrate dose upward to clinical effect or 25-50% of the maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Upward dose titration should not occur until after steady state is reached (at least 8 days for celecoxib after first dose in PMs). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider an alternate therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo.
flurbiprofen	CYP2C9	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2C9 with regards to taking flurbiprofen?	Initiate therapy with 25-50% of the lowest recommended starting dose. Titrate dose upward to clinical effect or 25-50% of the maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Upward dose titration should not occur until after steady state is reached (at least 8 days for celecoxib after first dose in PMs). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider an alternate therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo.
flurbiprofen	CYP2C9	What would be the clinical guidance for someone who is Indeterminate for CYP2C9 with regards to taking flurbiprofen?	No recommendation
ibuprofen	CYP2C9	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2C9 with regards to taking ibuprofen?	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.
ibuprofen	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.5 for CYP2C9 with regards to taking ibuprofen?	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.
ibuprofen	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2C9 with regards to taking ibuprofen?	Initiate therapy with lowest recommended starting dose. Titrate dose upward to clinical effect or maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Carefully monitor adverse events such as blood pressure and kidney function during course of therapy.
ibuprofen	CYP2C9	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.5 for CYP2C9 with regards to taking ibuprofen?	Initiate therapy with 25-50% of the lowest recommended starting dose. Titrate dose upward to clinical effect or 25-50% of the maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Upward dose titration should not occur until after steady state is reached (at least 8 days for celecoxib after first dose in PMs). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider an alternate therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo.
ibuprofen	CYP2C9	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2C9 with regards to taking ibuprofen?	Initiate therapy with 25-50% of the lowest recommended starting dose. Titrate dose upward to clinical effect or 25-50% of the maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Upward dose titration should not occur until after steady state is reached (at least 8 days for celecoxib after first dose in PMs). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider an alternate therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo.
ibuprofen	CYP2C9	What would be the clinical guidance for someone who is Indeterminate for CYP2C9 with regards to taking ibuprofen?	No recommendation
lornoxicam	CYP2C9	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2C9 with regards to taking lornoxicam?	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.
lornoxicam	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.5 for CYP2C9 with regards to taking lornoxicam?	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.
lornoxicam	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2C9 with regards to taking lornoxicam?	Initiate therapy with lowest recommended starting dose. Titrate dose upward to clinical effect or maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Carefully monitor adverse events such as blood pressure and kidney function during course of therapy.
lornoxicam	CYP2C9	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.5 for CYP2C9 with regards to taking lornoxicam?	Initiate therapy with 25-50% of the lowest recommended starting dose. Titrate dose upward to clinical effect or 25-50% of the maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Upward dose titration should not occur until after steady state is reached (at least 8 days for celecoxib after first dose in PMs). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider an alternate therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo.
lornoxicam	CYP2C9	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2C9 with regards to taking lornoxicam?	Initiate therapy with 25-50% of the lowest recommended starting dose. Titrate dose upward to clinical effect or 25-50% of the maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Upward dose titration should not occur until after steady state is reached (at least 8 days for celecoxib after first dose in PMs). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider an alternate therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo.
lornoxicam	CYP2C9	What would be the clinical guidance for someone who is Indeterminate for CYP2C9 with regards to taking lornoxicam?	No recommendation
chloramphenicol	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking chloramphenicol?	No reason to avoid based on G6PD status
chloramphenicol	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking chloramphenicol?	No reason to avoid based on G6PD status at standard doses
chloramphenicol	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking chloramphenicol?	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended
chloroquine	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking chloroquine?	No reason to avoid based on G6PD status
hydroxychloroquine	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking hydroxychloroquine?	No reason to avoid based on G6PD status
vitamin c	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking vitamin c?	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended
vitamin c	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking vitamin c?	No reason to avoid based on G6PD status at standard doses
vitamin c	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking vitamin c?	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.
vitamin k	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking vitamin k?	No reason to avoid based on G6PD status
vitamin k	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking vitamin k?	No reason to avoid based on G6PD status at standard doses
vitamin k	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking vitamin k?	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended
vitamin k	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking vitamin k?	No reason to avoid based on G6PD status at standard doses
vitamin k	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking vitamin k?	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.
citalopram	CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2C19 with regards to taking citalopram?	Consider a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19. If citalopram or escitalopram are clinically appropriate, and adequate efficacy is not achieved at standard maintenance dosing, consider titrating to a higher maintenance dose.
citalopram	CYP2C19	What would be the clinical guidance for someone who is Rapid Metabolizer for CYP2C19 with regards to taking citalopram?	Initiate therapy with recommended starting dose. If patient does not adequately respond to recommended maintenance dosing, consider titrating to a higher maintenance dose or switching to a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.
citalopram	CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer for CYP2C19 with regards to taking citalopram?	Initiate therapy with recommended starting dose
citalopram	CYP2C19	What would be the clinical guidance for someone who is Likely Intermediate Metabolizer for CYP2C19 with regards to taking citalopram?	Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose than normal metabolizers.
citalopram	CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer for CYP2C19 with regards to taking citalopram?	Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose than normal metabolizers.
citalopram	CYP2C19	What would be the clinical guidance for someone who is Likely Poor Metabolizer for CYP2C19 with regards to taking citalopram?	Consider a clinically appropriate antidepressant not predominantly metabolized by CYP2C19. If citalopram or escitalopram are clinically appropriate, consider a lower starting dose, slower titration schedule and 50% reduction of the standard maintenance dose as compared to normal metabolizers.
citalopram	CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer for CYP2C19 with regards to taking citalopram?	Consider a clinically appropriate antidepressant not predominantly metabolized by CYP2C19. If citalopram or escitalopram are clinically appropriate, consider a lower starting dose, slower titration schedule and 50% reduction of the standard maintenance dose as compared to normal metabolizers.
citalopram	CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2C19 with regards to taking citalopram?	No recommendation
escitalopram	CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2C19 with regards to taking escitalopram?	Consider a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19. If citalopram or escitalopram are clinically appropriate, and adequate efficacy is not achieved at standard maintenance dosing, consider titrating to a higher maintenance dose.
escitalopram	CYP2C19	What would be the clinical guidance for someone who is Rapid Metabolizer for CYP2C19 with regards to taking escitalopram?	Initiate therapy with recommended starting dose. If patient does not adequately respond to recommended maintenance dosing, consider titrating to a higher maintenance dose or switching to a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.
escitalopram	CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer for CYP2C19 with regards to taking escitalopram?	Initiate therapy with recommended starting dose
escitalopram	CYP2C19	What would be the clinical guidance for someone who is Likely Intermediate Metabolizer for CYP2C19 with regards to taking escitalopram?	Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose than normal metabolizers.
escitalopram	CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer for CYP2C19 with regards to taking escitalopram?	Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose than normal metabolizers.
escitalopram	CYP2C19	What would be the clinical guidance for someone who is Likely Poor Metabolizer for CYP2C19 with regards to taking escitalopram?	Consider a clinically appropriate antidepressant not predominantly metabolized by CYP2C19. If citalopram or escitalopram are clinically appropriate, consider a lower starting dose, slower titration schedule and 50% reduction of the standard maintenance dose as compared to normal metabolizers.
escitalopram	CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer for CYP2C19 with regards to taking escitalopram?	Consider a clinically appropriate antidepressant not predominantly metabolized by CYP2C19. If citalopram or escitalopram are clinically appropriate, consider a lower starting dose, slower titration schedule and 50% reduction of the standard maintenance dose as compared to normal metabolizers.
escitalopram	CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2C19 with regards to taking escitalopram?	No recommendation
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking clomipramine?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking clomipramine?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking clomipramine?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
tamoxifen	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 with regards to taking tamoxifen?	Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking clomipramine?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
fluvoxamine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 with regards to taking fluvoxamine?	Initiate therapy with recommended starting dose.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking clomipramine?	Initiate therapy with recommended starting dose.
tenoxicam	CYP2C9	What would be the clinical guidance for someone who is Indeterminate for CYP2C9 with regards to taking tenoxicam?	No recommendation
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking clomipramine?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking clomipramine?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking clomipramine?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking clomipramine?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and No Result for CYP2C19 with regards to taking clomipramine?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and No Result for CYP2C19 with regards to taking clomipramine?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
hydrocodone	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 with regards to taking hydrocodone?	No recommendation for hydrocodone therapy because of minimal evidence regarding adverse events or analgesia.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and No Result for CYP2C19 with regards to taking clomipramine?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and No Result for CYP2C19 with regards to taking clomipramine?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	Initiate therapy with recommended starting dose.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	Initiate therapy with recommended starting dose.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	Initiate therapy with recommended starting dose.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	Initiate therapy with recommended starting dose.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	Initiate therapy with recommended starting dose.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking clomipramine?	Initiate therapy with recommended starting dose.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking clomipramine?	Initiate therapy with recommended starting dose.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking clomipramine?	Initiate therapy with recommended starting dose.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking clomipramine?	Initiate therapy with recommended starting dose.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use. If clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use. If clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use. If clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use. If clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use. If clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	Initiate therapy with recommended starting dose.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and No Result for CYP2C19 with regards to taking clomipramine?	Initiate therapy with recommended starting dose.
hydrocodone	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 with regards to taking hydrocodone?	No recommendation for hydrocodone therapy because of minimal evidence regarding adverse events or analgesia.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking clomipramine?	No recommendation
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking clomipramine?	No recommendation
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking clomipramine?	No recommendation
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking clomipramine?	No recommendation
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking clomipramine?	No recommendation
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	Initiate therapy with recommended starting dose.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	Initiate therapy with recommended starting dose.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	Initiate therapy with recommended starting dose.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	Initiate therapy with recommended starting dose.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use. If clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use. If clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use. If clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use. If clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use. If clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and No Result for CYP2C19 with regards to taking clomipramine?	Initiate therapy with recommended starting dose.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and No Result for CYP2C19 with regards to taking clomipramine?	Initiate therapy with recommended starting dose.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and No Result for CYP2C19 with regards to taking clomipramine?	Initiate therapy with recommended starting dose.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and No Result for CYP2C19 with regards to taking clomipramine?	Initiate therapy with recommended starting dose.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use. If a clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use. If a clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking clomipramine?	Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use. If a clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and No Result for CYP2C19 with regards to taking clomipramine?	Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking clomipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking clomipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking clomipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking clomipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking clomipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking clomipramine?	Initiate therapy with recommended starting dose.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking clomipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking clomipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking clomipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking clomipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking clomipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking clomipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and No Result for CYP2C19 with regards to taking clomipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
codeine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 with regards to taking codeine?	Avoid codeine use because of potential for serious toxicity. If opioid use is warranted, consider a non-tramadol opioid.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and No Result for CYP2C19 with regards to taking clomipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and No Result for CYP2C19 with regards to taking clomipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and No Result for CYP2C19 with regards to taking clomipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and No Result for CYP2C19 with regards to taking clomipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and No Result for CYP2C19 with regards to taking clomipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and No Result for CYP2C19 with regards to taking clomipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and No Result for CYP2C19 with regards to taking clomipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and No Result for CYP2C19 with regards to taking clomipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and No Result for CYP2C19 with regards to taking clomipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
codeine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 with regards to taking codeine?	Avoid codeine use because of potential for serious toxicity. If opioid use is warranted, consider a non-tramadol opioid.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and No Result for CYP2C19 with regards to taking clomipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	No recommendation
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking clomipramine?	No recommendation
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and Indeterminate for CYP2C19 with regards to taking clomipramine?	No recommendation
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	No recommendation
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and No Result for CYP2C19 with regards to taking clomipramine?	No recommendation
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	Initiate therapy with recommended starting dose.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Indeterminate for CYP2C19 with regards to taking clomipramine?	No recommendation
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine?	Initiate therapy with recommended starting dose.
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking clomipramine?	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
clopidogrel	CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2C19 with regards to taking clopidogrel?	If considering clopidogrel, use at standard dose (75 mg/day)
clopidogrel	CYP2C19	What would be the clinical guidance for someone who is Rapid Metabolizer for CYP2C19 with regards to taking clopidogrel?	If considering clopidogrel, use at standard dose (75 mg/day)
clopidogrel	CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer for CYP2C19 with regards to taking clopidogrel?	If considering clopidogrel, use at standard dose (75 mg/day)
codeine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 with regards to taking codeine?	Avoid codeine use because of potential for serious toxicity. If opioid use is warranted, consider a non-tramadol opioid.
clopidogrel	CYP2C19	What would be the clinical guidance for someone who is Likely Intermediate Metabolizer for CYP2C19 with regards to taking clopidogrel?	Avoid standard dose clopidogrel (75 mg) if possible. Use prasugrel or ticagrelor at standard dose if no contraindication.
clopidogrel	CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer for CYP2C19 with regards to taking clopidogrel?	Avoid standard dose (75 mg) clopidogrel if possible. Use prasugrel or ticagrelor at standard dose if no contraindication.
clopidogrel	CYP2C19	What would be the clinical guidance for someone who is Likely Poor Metabolizer for CYP2C19 with regards to taking clopidogrel?	Avoid clopidogrel if possible. Use prasugrel or ticagrelor at standard dose if no contraindication.
clopidogrel	CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer for CYP2C19 with regards to taking clopidogrel?	Avoid clopidogrel if possible. Use prasugrel or ticagrelor at standard dose if no contraindication.
clopidogrel	CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2C19 with regards to taking clopidogrel?	No recommendation
clopidogrel	CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2C19 with regards to taking clopidogrel?	No recommendation
clopidogrel	CYP2C19	What would be the clinical guidance for someone who is Rapid Metabolizer for CYP2C19 with regards to taking clopidogrel?	No recommendation
clopidogrel	CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer for CYP2C19 with regards to taking clopidogrel?	If considering clopidogrel, use at standard dose (75 mg/day)
clopidogrel	CYP2C19	What would be the clinical guidance for someone who is Likely Intermediate Metabolizer for CYP2C19 with regards to taking clopidogrel?	No recommendation
clopidogrel	CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer for CYP2C19 with regards to taking clopidogrel?	No recommendation
dapsone	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking dapsone?	Avoid use
dapsone	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking dapsone?	Avoid use
clopidogrel	CYP2C19	What would be the clinical guidance for someone who is Likely Poor Metabolizer for CYP2C19 with regards to taking clopidogrel?	Avoid clopidogrel if possible. Use prasugrel or ticagrelor at standard dose if no contraindication.
clopidogrel	CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer for CYP2C19 with regards to taking clopidogrel?	Avoid clopidogrel if possible. Use prasugrel or ticagrelor at standard dose if no contraindication.
clopidogrel	CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2C19 with regards to taking clopidogrel?	No recommendation
clopidogrel	CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2C19 with regards to taking clopidogrel?	No recommendation
clopidogrel	CYP2C19	What would be the clinical guidance for someone who is Rapid Metabolizer for CYP2C19 with regards to taking clopidogrel?	No recommendation
clopidogrel	CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer for CYP2C19 with regards to taking clopidogrel?	If considering clopidogrel, use at standard dose (75 mg/day)
clopidogrel	CYP2C19	What would be the clinical guidance for someone who is Likely Intermediate Metabolizer for CYP2C19 with regards to taking clopidogrel?	Consider an alternative P2Y12 inhibitor at standard dose if clinically indicated and no contraindication.
clopidogrel	CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer for CYP2C19 with regards to taking clopidogrel?	Consider an alternative P2Y12 inhibitor at standard dose if clinically indicated and no contraindication.
clopidogrel	CYP2C19	What would be the clinical guidance for someone who is Likely Poor Metabolizer for CYP2C19 with regards to taking clopidogrel?	Avoid clopidogrel if possible. Consider an alternative P2Y12 inhibitor at standard dose if clinically indicated and no contraindication.
clopidogrel	CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer for CYP2C19 with regards to taking clopidogrel?	Avoid clopidogrel if possible. Consider an alternative P2Y12 inhibitor at standard dose if clinically indicated and no contraindication.
clopidogrel	CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2C19 with regards to taking clopidogrel?	No recommendation
codeine	CYP2D6	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 with regards to taking codeine?	No recommendation
codeine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 with regards to taking codeine?	Use codeine label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider a non-tramadol opioid.
codeine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 with regards to taking codeine?	Use codeine label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider a non-tramadol opioid.
codeine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 with regards to taking codeine?	Use codeine label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider a non-tramadol opioid.
codeine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 with regards to taking codeine?	Use codeine label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider a non-tramadol opioid.
codeine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 with regards to taking codeine?	Use codeine label recommended age- or weight-specific dosing.
codeine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 with regards to taking codeine?	Use codeine label recommended age- or weight-specific dosing.
codeine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 with regards to taking codeine?	Use codeine label recommended age- or weight-specific dosing.
codeine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 with regards to taking codeine?	Use codeine label recommended age- or weight-specific dosing.
codeine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 with regards to taking codeine?	Use codeine label recommended age- or weight-specific dosing.
codeine	CYP2D6	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 with regards to taking codeine?	Avoid codeine use because of possibility of diminished analgesia. If opioid use is warranted, consider a non-tramadol opioid.
codeine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 with regards to taking codeine?	Avoid codeine use because of potential for serious toxicity. If opioid use is warranted, consider a non-tramadol opioid.
codeine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 with regards to taking codeine?	Avoid codeine use because of potential for serious toxicity. If opioid use is warranted, consider a non-tramadol opioid.
codeine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 with regards to taking codeine?	Avoid codeine use because of potential for serious toxicity. If opioid use is warranted, consider a non-tramadol opioid.
codeine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 with regards to taking codeine?	Avoid codeine use because of potential for serious toxicity. If opioid use is warranted, consider a non-tramadol opioid.
codeine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 with regards to taking codeine?	Avoid codeine use because of potential for serious toxicity. If opioid use is warranted, consider a non-tramadol opioid.
codeine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 with regards to taking codeine?	Avoid codeine use because of potential for serious toxicity. If opioid use is warranted, consider a non-tramadol opioid.
codeine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 with regards to taking codeine?	Avoid codeine use because of potential for serious toxicity. If opioid use is warranted, consider a non-tramadol opioid.
codeine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 with regards to taking codeine?	Avoid codeine use because of potential for serious toxicity. If opioid use is warranted, consider a non-tramadol opioid.
dapsone	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking dapsone?	No reason to avoid based on G6PD status
dapsone	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking dapsone?	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.
dapsone	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking dapsone?	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.
pegloticase	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking pegloticase?	No reason to avoid based on G6PD status
pegloticase	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking pegloticase?	Avoid use
pegloticase	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking pegloticase?	Avoid use
pegloticase	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking pegloticase?	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.
pegloticase	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking pegloticase?	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.
rasburicase	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking rasburicase?	No reason to avoid based on G6PD status
rasburicase	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking rasburicase?	Avoid use
rasburicase	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking rasburicase?	Avoid use
rasburicase	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking rasburicase?	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.
rasburicase	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking rasburicase?	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.
desflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Malignant Hyperthermia Susceptibility for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking desflurane?	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.
desflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and No Result for CACNA1S with regards to taking desflurane?	No CACNA1S genotype is available. Based on RYR1 status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking doxepin?	Initiate therapy with recommended starting dose.
desflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking desflurane?	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.
desflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking desflurane?	Clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.
desflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Malignant Hyperthermia Susceptibility for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking desflurane?	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.
desflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Malignant Hyperthermia Susceptibility for RYR1 and No Result for CACNA1S with regards to taking desflurane?	Based on RYR1 status, halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.
desflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is No Result for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking desflurane?	Based on CACNA1S status, halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.
quinine	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking quinine?	No reason to avoid based on G6PD status at standard doses
desflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is No Result for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking desflurane?	No RYR1 genotype is available. Based on CACNA1S status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.
enflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Malignant Hyperthermia Susceptibility for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking enflurane?	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.
enflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking enflurane?	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.
enflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking enflurane?	Clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.
enflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Malignant Hyperthermia Susceptibility for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking enflurane?	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.
halothane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and No Result for CACNA1S with regards to taking halothane?	No CACNA1S genotype is available. Based on RYR1 status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.
enflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Malignant Hyperthermia Susceptibility for RYR1 and No Result for CACNA1S with regards to taking enflurane?	Based on RYR1 status, halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.
enflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is No Result for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking enflurane?	Based on CACNA1S status, halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.
enflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and No Result for CACNA1S with regards to taking enflurane?	No CACNA1S genotype is available. Based on RYR1 status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.
enflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is No Result for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking enflurane?	No RYR1 genotype is available. Based on CACNA1S status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.
halothane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Malignant Hyperthermia Susceptibility for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking halothane?	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.
halothane	RYR1;CACNA1S	What would be the clinical guidance for someone who is No Result for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking halothane?	No RYR1 genotype is available. Based on CACNA1S status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.
sevoflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and No Result for CACNA1S with regards to taking sevoflurane?	No CACNA1S genotype is available. Based on RYR1 status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.
halothane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking halothane?	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.
halothane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking halothane?	Clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.
halothane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Malignant Hyperthermia Susceptibility for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking halothane?	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.
halothane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Malignant Hyperthermia Susceptibility for RYR1 and No Result for CACNA1S with regards to taking halothane?	Based on RYR1 status, halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.
halothane	RYR1;CACNA1S	What would be the clinical guidance for someone who is No Result for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking halothane?	Based on CACNA1S status, halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.
sulfamethoxazole / trimethoprim	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking sulfamethoxazole / trimethoprim?	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.
isoflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Malignant Hyperthermia Susceptibility for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking isoflurane?	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.
isoflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking isoflurane?	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.
isoflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking isoflurane?	Clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.
isoflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Malignant Hyperthermia Susceptibility for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking isoflurane?	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.
isoflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Malignant Hyperthermia Susceptibility for RYR1 and No Result for CACNA1S with regards to taking isoflurane?	Based on RYR1 status, halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.
isoflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is No Result for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking isoflurane?	Based on CACNA1S status, halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.
isoflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and No Result for CACNA1S with regards to taking isoflurane?	No CACNA1S genotype is available. Based on RYR1 status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.
isoflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is No Result for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking isoflurane?	No RYR1 genotype is available. Based on CACNA1S status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.
methoxyflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Malignant Hyperthermia Susceptibility for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking methoxyflurane?	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.
methoxyflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking methoxyflurane?	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.
methoxyflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking methoxyflurane?	Clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.
sulfanilamide	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking sulfanilamide?	No reason to avoid based on G6PD status at standard doses
methoxyflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Malignant Hyperthermia Susceptibility for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking methoxyflurane?	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.
methoxyflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Malignant Hyperthermia Susceptibility for RYR1 and No Result for CACNA1S with regards to taking methoxyflurane?	Based on RYR1 status, halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.
methoxyflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is No Result for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking methoxyflurane?	Based on CACNA1S status, halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.
methoxyflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and No Result for CACNA1S with regards to taking methoxyflurane?	No CACNA1S genotype is available. Based on RYR1 status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.
methoxyflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is No Result for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking methoxyflurane?	No RYR1 genotype is available. Based on CACNA1S status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.
sevoflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is No Result for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking sevoflurane?	Based on CACNA1S status, halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.
sevoflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Malignant Hyperthermia Susceptibility for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking sevoflurane?	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.
sevoflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking sevoflurane?	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.
sevoflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking sevoflurane?	Clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.
sevoflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Malignant Hyperthermia Susceptibility for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking sevoflurane?	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.
sevoflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Malignant Hyperthermia Susceptibility for RYR1 and No Result for CACNA1S with regards to taking sevoflurane?	Based on RYR1 status, halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.
sevoflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is No Result for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking sevoflurane?	No RYR1 genotype is available. Based on CACNA1S status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.
succinylcholine	RYR1;CACNA1S	What would be the clinical guidance for someone who is Malignant Hyperthermia Susceptibility for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking succinylcholine?	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.
succinylcholine	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking succinylcholine?	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.
succinylcholine	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking succinylcholine?	Clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.
succinylcholine	RYR1;CACNA1S	What would be the clinical guidance for someone who is Malignant Hyperthermia Susceptibility for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking succinylcholine?	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.
desipramine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 with regards to taking desipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.
succinylcholine	RYR1;CACNA1S	What would be the clinical guidance for someone who is Malignant Hyperthermia Susceptibility for RYR1 and No Result for CACNA1S with regards to taking succinylcholine?	Based on RYR1 status, halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.
succinylcholine	RYR1;CACNA1S	What would be the clinical guidance for someone who is No Result for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking succinylcholine?	Based on CACNA1S status, halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.
succinylcholine	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and No Result for CACNA1S with regards to taking succinylcholine?	No CACNA1S genotype is available. Based on RYR1 status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.
succinylcholine	RYR1;CACNA1S	What would be the clinical guidance for someone who is No Result for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking succinylcholine?	No RYR1 genotype is available. Based on CACNA1S status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.
desipramine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 with regards to taking desipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.
desipramine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 with regards to taking desipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.
desipramine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 with regards to taking desipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.
desipramine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 with regards to taking desipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.
tolbutamide	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking tolbutamide?	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.
desipramine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 with regards to taking desipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.
desipramine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 with regards to taking desipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.
desipramine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 with regards to taking desipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.
desipramine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 with regards to taking desipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.
desipramine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 with regards to taking desipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.
desipramine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 with regards to taking desipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.
desipramine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 with regards to taking desipramine?	Initiate therapy with recommended starting dose
desipramine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 with regards to taking desipramine?	Initiate therapy with recommended starting dose
desipramine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 with regards to taking desipramine?	Initiate therapy with recommended starting dose
desipramine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 with regards to taking desipramine?	Initiate therapy with recommended starting dose
desipramine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 with regards to taking desipramine?	Initiate therapy with recommended starting dose
desipramine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 with regards to taking desipramine?	Consider a 25% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.
desipramine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 with regards to taking desipramine?	Consider a 25% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.
desipramine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 with regards to taking desipramine?	Consider a 25% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.
desipramine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 with regards to taking desipramine?	Consider a 25% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.
desipramine	CYP2D6	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 with regards to taking desipramine?	Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.
desipramine	CYP2D6	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 with regards to taking desipramine?	No recommendation
dexlansoprazole	CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2C19 with regards to taking dexlansoprazole?	Increase starting daily dose by 100%. Daily dose may be given in divided doses. Monitor for efficacy.
dexlansoprazole	CYP2C19	What would be the clinical guidance for someone who is Rapid Metabolizer for CYP2C19 with regards to taking dexlansoprazole?	Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses.Monitor for efficacy.
dexlansoprazole	CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer for CYP2C19 with regards to taking dexlansoprazole?	Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses.Monitor for efficacy.
dexlansoprazole	CYP2C19	What would be the clinical guidance for someone who is Likely Intermediate Metabolizer for CYP2C19 with regards to taking dexlansoprazole?	Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.
dexlansoprazole	CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer for CYP2C19 with regards to taking dexlansoprazole?	Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	Initiate therapy with recommended starting dose.
dexlansoprazole	CYP2C19	What would be the clinical guidance for someone who is Likely Poor Metabolizer for CYP2C19 with regards to taking dexlansoprazole?	Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.
dexlansoprazole	CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer for CYP2C19 with regards to taking dexlansoprazole?	Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.
dexlansoprazole	CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2C19 with regards to taking dexlansoprazole?	No recommendation
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	Initiate therapy with recommended starting dose.
tramadol	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 with regards to taking tramadol?	Use tramadol label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider non-codeine opioid.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking doxepin?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking doxepin?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking doxepin?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking doxepin?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
lovastatin	SLCO1B1	What would be the clinical guidance for someone who is Normal Function for SLCO1B1 with regards to taking lovastatin?	Prescribe desired starting dose and adjust doses based on disease-specific guidelines.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking doxepin?	Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking doxepin?	Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking doxepin?	Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
pantoprazole	CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer for CYP2C19 with regards to taking pantoprazole?	Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking doxepin?	Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking doxepin?	Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking doxepin?	Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking doxepin?	Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking doxepin?	Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	Initiate therapy with recommended starting dose.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking doxepin?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking doxepin?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking doxepin?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking doxepin?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking doxepin?	Initiate therapy with recommended starting dose.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and No Result for CYP2C19 with regards to taking doxepin?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and No Result for CYP2C19 with regards to taking doxepin?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and No Result for CYP2C19 with regards to taking doxepin?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and No Result for CYP2C19 with regards to taking doxepin?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	Initiate therapy with recommended starting dose.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	Initiate therapy with recommended starting dose.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking doxepin?	Initiate therapy with recommended starting dose.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking doxepin?	Initiate therapy with recommended starting dose.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking doxepin?	Initiate therapy with recommended starting dose.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use. If doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use. If doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use. If doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use. If doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use. If doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	Initiate therapy with recommended starting dose.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking doxepin?	Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking doxepin?	Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking doxepin?	Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking doxepin?	Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking doxepin?	Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking doxepin?	Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	Initiate therapy with recommended starting dose.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking doxepin?	Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking doxepin?	Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking doxepin?	Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking doxepin?	Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking doxepin?	No recommendation
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking doxepin?	No recommendation
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking doxepin?	No recommendation
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking doxepin?	No recommendation
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking doxepin?	No recommendation
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	Initiate therapy with recommended starting dose.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	Initiate therapy with recommended starting dose.
tramadol	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 with regards to taking tramadol?	Use tramadol label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider non-codeine opioid.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	Initiate therapy with recommended starting dose.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use. If doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use. If doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use. If doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use. If doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use. If doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and No Result for CYP2C19 with regards to taking doxepin?	Initiate therapy with recommended starting dose.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and No Result for CYP2C19 with regards to taking doxepin?	Initiate therapy with recommended starting dose.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and No Result for CYP2C19 with regards to taking doxepin?	Initiate therapy with recommended starting dose.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and No Result for CYP2C19 with regards to taking doxepin?	Initiate therapy with recommended starting dose.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and No Result for CYP2C19 with regards to taking doxepin?	Initiate therapy with recommended starting dose.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use. If a doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use. If a doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking doxepin?	Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use. If a doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and No Result for CYP2C19 with regards to taking doxepin?	Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
capecitabine	DPYD	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for DPYD with regards to taking capecitabine?	Based on genotype, there is no indication to change dose or therapy. Use label-recommended dosage and administration.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
capecitabine	DPYD	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.5 for DPYD with regards to taking capecitabine?	Reduce starting dose by 50% followed by titration of dose based on toxicity or therapeutic drug monitoring (if available).
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking doxepin?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking doxepin?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking doxepin?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking doxepin?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking doxepin?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking doxepin?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking doxepin?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking doxepin?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking doxepin?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking doxepin?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking doxepin?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2C9 and Increased Function for SLCO1B1 with regards to taking fluvastatin?	Prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and No Result for CYP2C19 with regards to taking doxepin?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and No Result for CYP2C19 with regards to taking doxepin?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and No Result for CYP2C19 with regards to taking doxepin?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and No Result for CYP2C19 with regards to taking doxepin?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and No Result for CYP2C19 with regards to taking doxepin?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and No Result for CYP2C19 with regards to taking doxepin?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and No Result for CYP2C19 with regards to taking doxepin?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and No Result for CYP2C19 with regards to taking doxepin?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and No Result for CYP2C19 with regards to taking doxepin?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and No Result for CYP2C19 with regards to taking doxepin?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and No Result for CYP2C19 with regards to taking doxepin?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	No recommendation
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking doxepin?	No recommendation
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and Indeterminate for CYP2C19 with regards to taking doxepin?	No recommendation
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	No recommendation
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2C9 and Indeterminate for SLCO1B1 with regards to taking fluvastatin?	Based on CYP2C9 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. SLCO1B1 phenotype could not be assigned based on genotyping.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and No Result for CYP2C19 with regards to taking doxepin?	No recommendation
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	Initiate therapy with recommended starting dose.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking doxepin?	Initiate therapy with recommended starting dose.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Indeterminate for CYP2C19 with regards to taking doxepin?	No recommendation
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking doxepin?	Initiate therapy with recommended starting dose.
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2C9 and No Result for SLCO1B1 with regards to taking fluvastatin?	Based on CYP2C9 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. SLCO1B1 genotype result is not available.
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking doxepin?	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
efavirenz	CYP2B6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2B6 with regards to taking efavirenz?	Initiate efavirenz with standard dosing (600 mg/day)
efavirenz	CYP2B6	What would be the clinical guidance for someone who is Rapid Metabolizer for CYP2B6 with regards to taking efavirenz?	Initiate efavirenz with standard dosing (600 mg/day)
efavirenz	CYP2B6	What would be the clinical guidance for someone who is Normal Metabolizer for CYP2B6 with regards to taking efavirenz?	Initiate efavirenz with standard dosing (600 mg/day)
efavirenz	CYP2B6	What would be the clinical guidance for someone who is Intermediate Metabolizer for CYP2B6 with regards to taking efavirenz?	Consider initiating efavirenz with decreased dose of 400 mg/day
efavirenz	CYP2B6	What would be the clinical guidance for someone who is Poor Metabolizer for CYP2B6 with regards to taking efavirenz?	Consider initiating efavirenz with decreased dose of 400 or 200 mg/day
efavirenz	CYP2B6	What would be the clinical guidance for someone who is Indeterminate for CYP2B6 with regards to taking efavirenz?	No recommendation
fluorouracil	DPYD	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for DPYD with regards to taking fluorouracil?	Based on genotype, there is no indication to change dose or therapy. Use label-recommended dosage and administration.
fluorouracil	DPYD	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.5 for DPYD with regards to taking fluorouracil?	Reduce starting dose by 50% followed by titration of dose based on toxicity or therapeutic drug monitoring (if available).
fluorouracil	DPYD	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for DPYD with regards to taking fluorouracil?	Reduce starting dose by 50% followed by titration of dose based on toxicity or therapeutic drug monitoring (if available). Patients with the c.2846A>T/c.2846A>T genotype may require >50% reduction in starting dose.
fluorouracil	DPYD	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.5 for DPYD with regards to taking fluorouracil?	Avoid use of 5-fluorouracil or 5-fluorouracil prodrug-based regimens. In the event, based on clinical advice, alternative agents are not considered a suitable therapeutic option, 5-fluorouracil should be administered at a strongly reduced dose with early therapeutic drug monitoring.
fluorouracil	DPYD	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for DPYD with regards to taking fluorouracil?	Avoid use of 5-fluorouracil or 5-fluorouracil prodrug-based regimens.
capecitabine	DPYD	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for DPYD with regards to taking capecitabine?	Reduce starting dose by 50% followed by titration of dose based on toxicity or therapeutic drug monitoring (if available). Patients with the c.2846A>T/c.2846A>T genotype may require >50% reduction in starting dose.
capecitabine	DPYD	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.5 for DPYD with regards to taking capecitabine?	Avoid use of 5-fluorouracil or 5-fluorouracil prodrug-based regimens. In the event, based on clinical advice, alternative agents are not considered a suitable therapeutic option, 5-fluorouracil should be administered at a strongly reduced dose with early therapeutic drug monitoring.
capecitabine	DPYD	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for DPYD with regards to taking capecitabine?	Avoid use of 5-fluorouracil or 5-fluorouracil prodrug-based regimens.
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2C9 and Possible Decreased Function for SLCO1B1 with regards to taking fluvastatin?	Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2C9 and Decreased Function for SLCO1B1 with regards to taking fluvastatin?	Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.5 for CYP2C9 and Possible Decreased Function for SLCO1B1 with regards to taking fluvastatin?	Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.5 for CYP2C9 and Decreased Function for SLCO1B1 with regards to taking fluvastatin?	Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2C9 and Normal Function for SLCO1B1 with regards to taking fluvastatin?	Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
fluvoxamine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 with regards to taking fluvoxamine?	Initiate therapy with recommended starting dose.
fluvoxamine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 with regards to taking fluvoxamine?	Initiate therapy with recommended starting dose.
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2C9 and Increased Function for SLCO1B1 with regards to taking fluvastatin?	Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.5 for CYP2C9 and Normal Function for SLCO1B1 with regards to taking fluvastatin?	Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.5 for CYP2C9 and Increased Function for SLCO1B1 with regards to taking fluvastatin?	Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2C9 and Normal Function for SLCO1B1 with regards to taking fluvastatin?	Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >40mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2C9 and Increased Function for SLCO1B1 with regards to taking fluvastatin?	Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >40mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.5 for CYP2C9 and Normal Function for SLCO1B1 with regards to taking fluvastatin?	Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >40mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.5 for CYP2C9 and Increased Function for SLCO1B1 with regards to taking fluvastatin?	Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >40mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2C9 and Poor Function for SLCO1B1 with regards to taking fluvastatin?	Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If patient is tolerating 40mg per day but higher potency is needed, a higher dose (>40mg) or an alternative statin or combination therapy (i.e. fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391) could be considered. Prescriber should be aware of possible increased risk for myopathy with fluvastatin especially with doses >40mg per day.
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2C9 and Possible Decreased Function for SLCO1B1 with regards to taking fluvastatin?	Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins).
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2C9 and Decreased Function for SLCO1B1 with regards to taking fluvastatin?	Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins).
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.5 for CYP2C9 and Possible Decreased Function for SLCO1B1 with regards to taking fluvastatin?	Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins).
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.5 for CYP2C9 and Decreased Function for SLCO1B1 with regards to taking fluvastatin?	Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins).
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2C9 and Poor Function for SLCO1B1 with regards to taking fluvastatin?	Prescribe an alternative statin depending on the desired potency (see Table 2 and Figure 1 of PMID: 35152405 for recommendations for alternative statins).
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.5 for CYP2C9 and Poor Function for SLCO1B1 with regards to taking fluvastatin?	Prescribe an alternative statin depending on the desired potency (see Table 2 and Figure 1 of PMID: 35152405 for recommendations for alternative statins).
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2C9 and Poor Function for SLCO1B1 with regards to taking fluvastatin?	Prescribe an alternative statin depending on the desired potency. (see Table 2 and Figure 1 of PMID: 35152405 for recommendations for alternative statins).
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.5 for CYP2C9 and Poor Function for SLCO1B1 with regards to taking fluvastatin?	Prescribe an alternative statin depending on the desired potency. (see Table 2 and Figure 1 of PMID: 35152405 for recommendations for alternative statins).
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2C9 and Normal Function for SLCO1B1 with regards to taking fluvastatin?	Prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines.
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2C9 and Possible Decreased Function for SLCO1B1 with regards to taking fluvastatin?	Prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >40mg per day.
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2C9 and Decreased Function for SLCO1B1 with regards to taking fluvastatin?	Prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >40mg per day.
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Indeterminate for CYP2C9 and Possible Decreased Function for SLCO1B1 with regards to taking fluvastatin?	Based on SLCO1B1 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >40mg per day. CYP2C9 phenotype could not be assigned based on genotyping.
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Indeterminate for CYP2C9 and Decreased Function for SLCO1B1 with regards to taking fluvastatin?	Based on SLCO1B1 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >40mg per day. CYP2C9 phenotype could not be assigned based on genotyping.
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Indeterminate for CYP2C9 and Increased Function for SLCO1B1 with regards to taking fluvastatin?	Based on SLCO1B1 status, prescribe desired starting dose and adjust doses based on disease-specific guidelines. CYP2C9 phenotype could not be assigned based on genotyping.
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Indeterminate for CYP2C9 and Indeterminate for SLCO1B1 with regards to taking fluvastatin?	n/a
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Indeterminate for CYP2C9 and No Result for SLCO1B1 with regards to taking fluvastatin?	n/a
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Indeterminate for CYP2C9 and Normal Function for SLCO1B1 with regards to taking fluvastatin?	Based on SLCO1B1 status, prescribe desired starting dose and adjust doses based on disease-specific guidelines. CYP2C9 phenotype could not be assigned based on genotyping.
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Indeterminate for CYP2C9 and Poor Function for SLCO1B1 with regards to taking fluvastatin?	Based on SLCO1B1 status, prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If patient is tolerating 40mg per day but higher potency is needed, a higher dose (>40mg) or an alternative statin (see Figure 1 of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. fluvastatin plus non-statin guideline directed medical therapy)(PMID: 30423391) could be considered. Prescriber should be aware of possible increased risk for myopathy with fluvastatin especially with doses >40mg per day. CYP2C9 phenotype could not be assigned based on genotyping.
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2C9 and Indeterminate for SLCO1B1 with regards to taking fluvastatin?	Based on CYP2C9 status, prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >40mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391). SLCO1B1 phenotype could not be assigned based on genotyping.
fluvoxamine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 with regards to taking fluvoxamine?	Initiate therapy with recommended starting dose.
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.5 for CYP2C9 and Indeterminate for SLCO1B1 with regards to taking fluvastatin?	Based on CYP2C9 status, prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >40mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391). SLCO1B1 phenotype could not be assigned based on genotyping.
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2C9 and No Result for SLCO1B1 with regards to taking fluvastatin?	Based on CYP2C9 status, prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >40mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391). SLCO1B1 genotype result is not available.
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.5 for CYP2C9 and No Result for SLCO1B1 with regards to taking fluvastatin?	Based on CYP2C9 status, prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >40mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391). SLCO1B1 genotype result is not available.
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2C9 and Decreased Function for SLCO1B1 with regards to taking fluvastatin?	Based on SLCO1B1 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >40mg per day. CYP2C9 genotype result is not available.
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2C9 and Increased Function for SLCO1B1 with regards to taking fluvastatin?	Based on SLCO1B1 status, prescribe desired starting dose and adjust doses based on disease-specific guidelines. CYP2C9 genotype result is not available.
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2C9 and Indeterminate for SLCO1B1 with regards to taking fluvastatin?	n/a
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2C9 and Normal Function for SLCO1B1 with regards to taking fluvastatin?	Based on SLCO1B1 status, prescribe desired starting dose and adjust doses based on disease-specific guidelines. CYP2C9 genotype result is not available.
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2C9 and Poor Function for SLCO1B1 with regards to taking fluvastatin?	Based on SLCO1B1 status, prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If patient is tolerating 40mg per day but higher potency is needed, a higher dose (>40mg) or an alternative statin (see Figure 1 of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391) could be considered. Prescriber should be aware of possible increased risk for myopathy with fluvastatin especially with doses >40mg per day. CYP2C9 genotype result is not available.
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2C9 and Possible Decreased Function for SLCO1B1 with regards to taking fluvastatin?	Based on SLCO1B1 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >40mg per day. CYP2C9 genotype result is not available.
fluvoxamine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 with regards to taking fluvoxamine?	Initiate therapy with recommended starting dose.
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2C9 and Indeterminate for SLCO1B1 with regards to taking fluvastatin?	Based on CYP2C9 status, prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391). SLCO1B1 phenotype could not be assigned based on genotyping.
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.5 for CYP2C9 and Indeterminate for SLCO1B1 with regards to taking fluvastatin?	Based on CYP2C9 status, prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391). SLCO1B1 phenotype could not be assigned based on genotyping.
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2C9 and No Result for SLCO1B1 with regards to taking fluvastatin?	Based on CYP2C9 status, prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391). SLCO1B1 genotype result is not available.
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.5 for CYP2C9 and No Result for SLCO1B1 with regards to taking fluvastatin?	Based on CYP2C9 status, prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391). SLCO1B1 genotype result is not available.
fluvoxamine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 with regards to taking fluvoxamine?	No recommendation due to lack of evidence
fluvoxamine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 with regards to taking fluvoxamine?	No recommendation due to lack of evidence
fluvoxamine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 with regards to taking fluvoxamine?	No recommendation due to lack of evidence
fluvoxamine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 with regards to taking fluvoxamine?	No recommendation due to lack of evidence
fluvoxamine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 with regards to taking fluvoxamine?	No recommendation due to lack of evidence
fluvoxamine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 with regards to taking fluvoxamine?	No recommendation due to lack of evidence
fluvoxamine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 with regards to taking fluvoxamine?	No recommendation due to lack of evidence
fluvoxamine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 with regards to taking fluvoxamine?	No recommendation due to lack of evidence
fluvoxamine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 with regards to taking fluvoxamine?	No recommendation due to lack of evidence
fluvoxamine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 with regards to taking fluvoxamine?	No recommendation due to lack of evidence
fluvoxamine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 with regards to taking fluvoxamine?	No recommendation due to lack of evidence
fluvoxamine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 with regards to taking fluvoxamine?	Initiate therapy with recommended starting dose.
fluvoxamine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 with regards to taking fluvoxamine?	Initiate therapy with recommended starting dose.
fluvoxamine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 with regards to taking fluvoxamine?	Initiate therapy with recommended starting dose.
fluvoxamine	CYP2D6	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 with regards to taking fluvoxamine?	Consider a 25-50% lower starting dose and slower titration schedule as compared to normal metabolizers or consider a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2D6.
fluvoxamine	CYP2D6	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 with regards to taking fluvoxamine?	No recommendation
hydrocodone	CYP2D6	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 with regards to taking hydrocodone?	No recommendation
hydrocodone	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 with regards to taking hydrocodone?	Use hydrocodone label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider non-codeine or non-tramadol opioid.
hydrocodone	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 with regards to taking hydrocodone?	Use hydrocodone label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider non-codeine or non-tramadol opioid.
hydrocodone	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 with regards to taking hydrocodone?	Use hydrocodone label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider non-codeine or non-tramadol opioid.
hydrocodone	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 with regards to taking hydrocodone?	Use hydrocodone label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider non-codeine or non-tramadol opioid.
hydrocodone	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 with regards to taking hydrocodone?	Use hydrocodone label recommended age- or weight-specific dosing.
hydrocodone	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 with regards to taking hydrocodone?	Use hydrocodone label recommended age- or weight-specific dosing.
hydrocodone	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 with regards to taking hydrocodone?	Use hydrocodone label recommended age- or weight-specific dosing.
hydrocodone	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 with regards to taking hydrocodone?	Use hydrocodone label recommended age- or weight-specific dosing.
hydrocodone	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 with regards to taking hydrocodone?	Use hydrocodone label recommended age- or weight-specific dosing.
hydrocodone	CYP2D6	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 with regards to taking hydrocodone?	Use hydrocodone label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider non-codeine and non-tramadol opioid.
hydrocodone	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 with regards to taking hydrocodone?	No recommendation for hydrocodone therapy because of minimal evidence regarding adverse events or analgesia.
hydrocodone	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 with regards to taking hydrocodone?	No recommendation for hydrocodone therapy because of minimal evidence regarding adverse events or analgesia.
hydrocodone	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 with regards to taking hydrocodone?	No recommendation for hydrocodone therapy because of minimal evidence regarding adverse events or analgesia.
hydrocodone	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 with regards to taking hydrocodone?	No recommendation for hydrocodone therapy because of minimal evidence regarding adverse events or analgesia.
hydrocodone	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 with regards to taking hydrocodone?	No recommendation for hydrocodone therapy because of minimal evidence regarding adverse events or analgesia.
hydrocodone	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 with regards to taking hydrocodone?	No recommendation for hydrocodone therapy because of minimal evidence regarding adverse events or analgesia.
hydrocodone	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 with regards to taking hydrocodone?	No recommendation for hydrocodone therapy because of minimal evidence regarding adverse events or analgesia.
hydrocodone	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 with regards to taking hydrocodone?	No recommendation for hydrocodone therapy because of minimal evidence regarding adverse events or analgesia.
hydrocodone	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 with regards to taking hydrocodone?	No recommendation for hydrocodone therapy because of minimal evidence regarding adverse events or analgesia.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use. If a imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	Initiate therapy with recommended starting dose.
phenazopyridine	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking phenazopyridine?	No reason to avoid based on G6PD status at standard doses
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	Initiate therapy with recommended starting dose.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	Initiate therapy with recommended starting dose.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	Initiate therapy with recommended starting dose.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	Initiate therapy with recommended starting dose.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2B6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking sertraline?	Initiate therapy with recommended starting dose.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	No recommendation
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	Initiate therapy with recommended starting dose.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use. If a imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking imipramine?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking imipramine?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking imipramine?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking imipramine?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking imipramine?	Initiate therapy with recommended starting dose.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking imipramine?	Initiate therapy with recommended starting dose.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking imipramine?	Initiate therapy with recommended starting dose.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking imipramine?	Initiate therapy with recommended starting dose.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking imipramine?	Initiate therapy with recommended starting dose.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking imipramine?	No recommendation
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking imipramine?	Initiate therapy with recommended starting dose.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use. If imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use. If imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use. If imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use. If imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use. If imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	Initiate therapy with recommended starting dose.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking imipramine?	Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking imipramine?	Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking imipramine?	Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking imipramine?	Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking imipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking imipramine?	Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking imipramine?	Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking imipramine?	Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking imipramine?	Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking imipramine?	Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking imipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.
phenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 negative for HLA-B with regards to taking phenytoin?	No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking imipramine?	Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking imipramine?	Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking imipramine?	Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking imipramine?	Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking imipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking imipramine?	Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking imipramine?	Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking imipramine?	Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking imipramine?	Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking imipramine?	Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	Initiate therapy with recommended starting dose.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.
phenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 negative for HLA-B with regards to taking phenytoin?	No recommendation
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking imipramine?	Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking imipramine?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking imipramine?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking imipramine?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking imipramine?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking imipramine?	No recommendation
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking imipramine?	No recommendation
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking imipramine?	No recommendation
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking imipramine?	No recommendation
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking imipramine?	No recommendation
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	Initiate therapy with recommended starting dose.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking imipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking imipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking imipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking imipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking imipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking imipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking imipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking imipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and Indeterminate for CYP2C19 with regards to taking imipramine?	No recommendation
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Indeterminate for CYP2C19 with regards to taking imipramine?	No recommendation
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	Initiate therapy with recommended starting dose.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use. If a imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	Initiate therapy with recommended starting dose.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2B6 and Indeterminate for CYP2C19 with regards to taking sertraline?	No recommendation
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	No recommendation
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking imipramine?	Initiate therapy with recommended starting dose.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and No Result for CYP2C19 with regards to taking imipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use. If imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use. If imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
lovastatin	SLCO1B1	What would be the clinical guidance for someone who is Increased Function for SLCO1B1 with regards to taking lovastatin?	Prescribe desired starting dose and adjust doses based on disease-specific guidelines.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use. If imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use. If imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use. If imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
tamoxifen	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 with regards to taking tamoxifen?	Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking imipramine?	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and No Result for CYP2C19 with regards to taking imipramine?	Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and No Result for CYP2C19 with regards to taking imipramine?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and No Result for CYP2C19 with regards to taking imipramine?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and No Result for CYP2C19 with regards to taking imipramine?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and No Result for CYP2C19 with regards to taking imipramine?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and No Result for CYP2C19 with regards to taking imipramine?	Initiate therapy with recommended starting dose.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and No Result for CYP2C19 with regards to taking imipramine?	Initiate therapy with recommended starting dose.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and No Result for CYP2C19 with regards to taking imipramine?	Initiate therapy with recommended starting dose.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and No Result for CYP2C19 with regards to taking imipramine?	Initiate therapy with recommended starting dose.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and No Result for CYP2C19 with regards to taking imipramine?	Initiate therapy with recommended starting dose.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and No Result for CYP2C19 with regards to taking imipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and No Result for CYP2C19 with regards to taking imipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and No Result for CYP2C19 with regards to taking imipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and No Result for CYP2C19 with regards to taking imipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and No Result for CYP2C19 with regards to taking imipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and No Result for CYP2C19 with regards to taking imipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and No Result for CYP2C19 with regards to taking imipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and No Result for CYP2C19 with regards to taking imipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and No Result for CYP2C19 with regards to taking imipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and No Result for CYP2C19 with regards to taking imipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and No Result for CYP2C19 with regards to taking imipramine?	No recommendation
ivacaftor	CFTR	What would be the clinical guidance for someone who is ivacaftor non-responsive in CF patients for CFTR with regards to taking ivacaftor?	Ivacaftor is not recommended
ivacaftor	CFTR	What would be the clinical guidance for someone who is ivacaftor responsive in CF patients for CFTR with regards to taking ivacaftor?	Use ivacaftor according to the product label
lovastatin	SLCO1B1	What would be the clinical guidance for someone who is Possible Decreased Function for SLCO1B1 with regards to taking lovastatin?	Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If lovastatin therapy is warranted, limit dose to ≤20mg/day.
lovastatin	SLCO1B1	What would be the clinical guidance for someone who is Decreased Function for SLCO1B1 with regards to taking lovastatin?	Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If lovastatin therapy is warranted, limit dose to ≤20mg/day.
lovastatin	SLCO1B1	What would be the clinical guidance for someone who is Poor Function for SLCO1B1 with regards to taking lovastatin?	Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins).
lovastatin	SLCO1B1	What would be the clinical guidance for someone who is Indeterminate for SLCO1B1 with regards to taking lovastatin?	No recommendation
meloxicam	CYP2C9	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2C9 with regards to taking meloxicam?	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.
meloxicam	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.5 for CYP2C9 with regards to taking meloxicam?	Initiate therapy with recommended starting dose. In accordance with the meloxicam prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.
meloxicam	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2C9 with regards to taking meloxicam?	Initiate therapy with 50% of the lowest recommended starting dose. Titrate dose upward to clinical effect or 50% of the maximum recommended dose with caution. In accordance with the meloxicam prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Upward dose titration should not occur until after steady state is reached (at least 7 days). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider alternative therapy. Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (see CPIC THERAPEUTIC RECOMMENDATIONS FOR CELECOXIB, FLURBIPROFEN, LORNOXICAM, AND IBUPROFEN BASED ON CYP2C9 PHENOTYPE).
meloxicam	CYP2C9	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.5 for CYP2C9 with regards to taking meloxicam?	Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (see CPIC THERAPEUTIC RECOMMENDATIONS FOR CELECOXIB, FLURBIPROFEN, LORNOXICAM, AND IBUPROFEN BASED ON CYP2C9 PHENOTYPE).
meloxicam	CYP2C9	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2C9 with regards to taking meloxicam?	Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (see CPIC THERAPEUTIC RECOMMENDATIONS FOR CELECOXIB, FLURBIPROFEN, LORNOXICAM, AND IBUPROFEN BASED ON CYP2C9 PHENOTYPE).
meloxicam	CYP2C9	What would be the clinical guidance for someone who is Indeterminate for CYP2C9 with regards to taking meloxicam?	No recommendation
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is Indeterminate for TPMT and Indeterminate for NUDT15 with regards to taking mercaptopurine?	Neither TPMT or NUDT15 phenotype could be assigned based on genotyping performed. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.
nortriptyline	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 with regards to taking nortriptyline?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is Possible Intermediate Metabolizer for TPMT and Indeterminate for NUDT15 with regards to taking mercaptopurine?	Based on TPMT status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is ≥ 75 mg/m2/day or ≥ 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201,18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended. NUDT15 phenotype could not be assigned based on genotyping. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is Intermediate Metabolizer for TPMT and Indeterminate for NUDT15 with regards to taking mercaptopurine?	Based on TPMT status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is ≥ 75 mg/m2/day or ≥ 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201,18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended. NUDT15 phenotype could not be assigned based on genotyping. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is Normal Metabolizer for TPMT and Indeterminate for NUDT15 with regards to taking mercaptopurine?	Based on TPMT status, start with normal starting dose (e.g., 75 mg/m2/day or 1.5 mg/kg/day) and adjust doses of mercaptopurine (and of any other myelosuppressive therapy) without any special emphasis on mercaptopurine compared to other agents. Allow at least 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 16401827, 11302950). NUDT15 phenotype could not be assigned based on genotyping. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is Poor Metabolizer for TPMT and Indeterminate for NUDT15 with regards to taking mercaptopurine?	Based on TPMT status, for malignancy, start with drastically reduced doses (reduce daily dose by 10-fold and reduce frequency to thrice weekly instead of daily, e.g., 10 mg/m2/day given just 3 days/week) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201, 1960624, 11302950, 16530532). NUDT15 phenotype could not be assigned based on genotyping. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is No Result for TPMT and Indeterminate for NUDT15 with regards to taking mercaptopurine?	NUDT15 phenotype could not be assigned based on genotyping performed and there is no TPMT genotype result result. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is Indeterminate for TPMT and No Result for NUDT15 with regards to taking mercaptopurine?	TPMT phenotype could not be assigned based on genotyping performed and there is no NUDT15 genotype result available. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.
nortriptyline	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 with regards to taking nortriptyline?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is Possible Intermediate Metabolizer for TPMT and No Result for NUDT15 with regards to taking mercaptopurine?	Based on TPMT status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is ≥ 75 mg/m2/day or ≥ 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201,18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended. NUDT15 genotype result is not available. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is Intermediate Metabolizer for TPMT and No Result for NUDT15 with regards to taking mercaptopurine?	Based on TPMT status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is ≥ 75 mg/m2/day or ≥ 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201,18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended. NUDT15 genotype result is not available. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is Normal Metabolizer for TPMT and No Result for NUDT15 with regards to taking mercaptopurine?	Based on TPMT status, start with normal starting dose (e.g., 75 mg/m2/day or 1.5 mg/kg/day) and adjust doses of mercaptopurine (and of any other myelosuppressive therapy) without any special emphasis on mercaptopurine compared to other agents. Allow at least 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 16401827, 11302950). NUDT15 genotype result is not available. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is Poor Metabolizer for TPMT and No Result for NUDT15 with regards to taking mercaptopurine?	Based on TPMT status, for malignancy, start with drastically reduced doses (reduce daily dose by 10-fold and reduce frequency to thrice weekly instead of daily, e.g., 10 mg/m2/day given just 3 days/week) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201, 1960624, 11302950, 16530532). NUDT15 genotype result is not available. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is Indeterminate for TPMT and Intermediate Metabolizer for NUDT15 with regards to taking mercaptopurine?	Based NUDT15 status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is ≥75 mg/m2/day or ≥ 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201, 18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended. TPMT phenotype could not be assigned based on genotyping. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.
nortriptyline	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 with regards to taking nortriptyline?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is Possible Intermediate Metabolizer for TPMT and Intermediate Metabolizer for NUDT15 with regards to taking mercaptopurine?	Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is ≥ 75 mg/m2/day or ≥ 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201,18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended.
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is Intermediate Metabolizer for TPMT and Intermediate Metabolizer for NUDT15 with regards to taking mercaptopurine?	Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is ≥ 75 mg/m2/day or ≥ 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201,18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended.
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is Normal Metabolizer for TPMT and Intermediate Metabolizer for NUDT15 with regards to taking mercaptopurine?	Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is ≥75 mg/m2/day or ≥ 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201, 18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended.
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is Poor Metabolizer for TPMT and Intermediate Metabolizer for NUDT15 with regards to taking mercaptopurine?	For malignancy, start with drastically reduced doses (reduce daily dose by 10-fold and reduce frequency to thrice weekly instead of daily, e.g., 10 mg/m2/day given just 3 days/week) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201, 1960624, 11302950, 16530532).
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is No Result for TPMT and Intermediate Metabolizer for NUDT15 with regards to taking mercaptopurine?	Based NUDT15 status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is ≥75 mg/m2/day or ≥ 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201, 18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended. TPMT genotype result is not available. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.
tamoxifen	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 with regards to taking tamoxifen?	Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is Indeterminate for TPMT and Normal Metabolizer for NUDT15 with regards to taking mercaptopurine?	Based on NUDT15 status, start with normal starting dose (e.g., 75 mg/m2/day or 1.5 mg/kg/day) and adjust doses of mercaptopurine (and of any other myelosuppressive therapy) without any special emphasis on mercaptopurine compared to other agents. Allow at least 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 16401827, 11302950). TPMT phenotype could not be assigned based on genotyping performed. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is Possible Intermediate Metabolizer for TPMT and Normal Metabolizer for NUDT15 with regards to taking mercaptopurine?	Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is ≥ 75 mg/m2/day or ≥ 1.5 mg/kg/day (e.g. start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201,18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended.
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is Intermediate Metabolizer for TPMT and Normal Metabolizer for NUDT15 with regards to taking mercaptopurine?	Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is ≥ 75 mg/m2/day or ≥ 1.5 mg/kg/day (e.g. start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201,18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended.
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is Normal Metabolizer for TPMT and Normal Metabolizer for NUDT15 with regards to taking mercaptopurine?	Start with normal starting dose (e.g., 75 mg/m2/day or 1.5 mg/kg/day) and adjust doses of mercaptopurine (and of any other myelosuppressive therapy) without any special emphasis on mercaptopurine compared to other agents. Allow at least 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 16401827, 11302950).
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is Poor Metabolizer for TPMT and Normal Metabolizer for NUDT15 with regards to taking mercaptopurine?	For malignancy, start with drastically reduced doses (reduce daily dose by 10-fold and reduce frequency to thrice weekly instead of daily, e.g., 10 mg/m2/day given just 3 days/week) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201, 1960624, 11302950, 16530532).
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is No Result for TPMT and Normal Metabolizer for NUDT15 with regards to taking mercaptopurine?	Based on NUDT15 status, start with normal starting dose (e.g., 75 mg/m2/day or 1.5 mg/kg/day) and adjust doses of mercaptopurine (and of any other myelosuppressive therapy) without any special emphasis on mercaptopurine compared to other agents. Allow at least 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 16401827, 11302950). TPMT genotype result is not available. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.
tamoxifen	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 with regards to taking tamoxifen?	Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is Indeterminate for TPMT and Poor Metabolizer for NUDT15 with regards to taking mercaptopurine?	Based on NUDT15 status, for malignancy, initiate dose at 10 mg/m2/day and adjust dose based on myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201, 1960624, 11302950, 16530532). TPMT phenotype could not be assigned based on genotyping performed. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is Possible Intermediate Metabolizer for TPMT and Poor Metabolizer for NUDT15 with regards to taking mercaptopurine?	For malignancy, initiate dose at 10 mg/m2/day and adjust dose based on myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201, 1960624, 11302950, 16530532).
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is Intermediate Metabolizer for TPMT and Poor Metabolizer for NUDT15 with regards to taking mercaptopurine?	For malignancy, initiate dose at 10 mg/m2/day and adjust dose based on myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201, 1960624, 11302950, 16530532).
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is Normal Metabolizer for TPMT and Poor Metabolizer for NUDT15 with regards to taking mercaptopurine?	For malignancy, initiate dose at 10 mg/m2/day and adjust dose based on myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201, 1960624, 11302950, 16530532).
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is Poor Metabolizer for TPMT and Poor Metabolizer for NUDT15 with regards to taking mercaptopurine?	For malignancy, start with drastically reduced doses (reduce daily dose by 10-fold and reduce frequency to thrice weekly instead of daily, e.g., 10 mg/m2/day given just 3 days/week) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201, 1960624, 11302950, 16530532).
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is No Result for TPMT and Poor Metabolizer for NUDT15 with regards to taking mercaptopurine?	Based on NUDT15 status, for malignancy, initiate dose at 10 mg/m2/day and adjust dose based on myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201, 1960624, 11302950, 16530532). TPMT genotype result is not available. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer for CYP2B6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking sertraline?	Initiate therapy with recommended starting dose.
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is Indeterminate for TPMT and Possible Intermediate Metabolizer for NUDT15 with regards to taking mercaptopurine?	Based on NUDT15 status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is ≥75 mg/m2/day or ≥ 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201, 18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended. TPMT phenotype could not be assigned based on genotyping performed. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is Possible Intermediate Metabolizer for TPMT and Possible Intermediate Metabolizer for NUDT15 with regards to taking mercaptopurine?	Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is ≥ 75 mg/m2/day or ≥ 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201,18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended.
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is Intermediate Metabolizer for TPMT and Possible Intermediate Metabolizer for NUDT15 with regards to taking mercaptopurine?	Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is ≥ 75 mg/m2/day or ≥ 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201,18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended.
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is Normal Metabolizer for TPMT and Possible Intermediate Metabolizer for NUDT15 with regards to taking mercaptopurine?	Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is ≥75 mg/m2/day or ≥ 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201, 18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended.
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is Poor Metabolizer for TPMT and Possible Intermediate Metabolizer for NUDT15 with regards to taking mercaptopurine?	For malignancy, start with drastically reduced doses (reduce daily dose by 10-fold and reduce frequency to thrice weekly instead of daily, e.g., 10 mg/m2/day given just 3 days/week) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201, 1960624, 11302950, 16530532).
tamoxifen	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 with regards to taking tamoxifen?	Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is No Result for TPMT and Possible Intermediate Metabolizer for NUDT15 with regards to taking mercaptopurine?	Based on NUDT15 status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is ≥75 mg/m2/day or ≥ 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201, 18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended. TPMT genotype result is not available. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.
methylene blue	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking methylene blue?	No reason to avoid ased on G6PD status
methylene blue	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking methylene blue?	Avoid use
methylene blue	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking methylene blue?	Avoid use
methylene blue	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking methylene blue?	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.
methylene blue	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking methylene blue?	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.
nitrofurantoin	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking nitrofurantoin?	No reason to avoid based on G6PD status
nitrofurantoin	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking nitrofurantoin?	Use at standard doses with caution and with close monitoring for anemia
nitrofurantoin	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking nitrofurantoin?	Avoid
nitrofurantoin	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking nitrofurantoin?	If deemed necessary to ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.
nitrofurantoin	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking nitrofurantoin?	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.
nortriptyline	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 with regards to taking nortriptyline?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.
nortriptyline	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 with regards to taking nortriptyline?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.
phenazopyridine	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking phenazopyridine?	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended
nortriptyline	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 with regards to taking nortriptyline?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.
nortriptyline	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 with regards to taking nortriptyline?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.
nortriptyline	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 with regards to taking nortriptyline?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.
nortriptyline	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 with regards to taking nortriptyline?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.
nortriptyline	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 with regards to taking nortriptyline?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.
nortriptyline	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 with regards to taking nortriptyline?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.
nortriptyline	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 with regards to taking nortriptyline?	Initiate therapy with recommended starting dose
nortriptyline	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 with regards to taking nortriptyline?	Initiate therapy with recommended starting dose
nortriptyline	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 with regards to taking nortriptyline?	Initiate therapy with recommended starting dose
nortriptyline	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 with regards to taking nortriptyline?	Initiate therapy with recommended starting dose
nortriptyline	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 with regards to taking nortriptyline?	Initiate therapy with recommended starting dose
omeprazole	CYP2C19	What would be the clinical guidance for someone who is Likely Intermediate Metabolizer for CYP2C19 with regards to taking omeprazole?	Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.
nortriptyline	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 with regards to taking nortriptyline?	Consider a 25% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.
nortriptyline	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 with regards to taking nortriptyline?	Consider a 25% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.
nortriptyline	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 with regards to taking nortriptyline?	Consider a 25% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.
nortriptyline	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 with regards to taking nortriptyline?	Consider a 25% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.
nortriptyline	CYP2D6	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 with regards to taking nortriptyline?	Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider a 50% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.
nortriptyline	CYP2D6	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 with regards to taking nortriptyline?	No recommendation
omeprazole	CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2C19 with regards to taking omeprazole?	Increase starting daily dose by 100%. Daily dose may be given in divided doses. Monitor for efficacy.
omeprazole	CYP2C19	What would be the clinical guidance for someone who is Rapid Metabolizer for CYP2C19 with regards to taking omeprazole?	Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses.Monitor for efficacy.
omeprazole	CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer for CYP2C19 with regards to taking omeprazole?	Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses.Monitor for efficacy.
omeprazole	CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer for CYP2C19 with regards to taking omeprazole?	Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.
omeprazole	CYP2C19	What would be the clinical guidance for someone who is Likely Poor Metabolizer for CYP2C19 with regards to taking omeprazole?	Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.
omeprazole	CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer for CYP2C19 with regards to taking omeprazole?	Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.
omeprazole	CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2C19 with regards to taking omeprazole?	No recommendation
lansoprazole	CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2C19 with regards to taking lansoprazole?	Increase starting daily dose by 100%. Daily dose may be given in divided doses. Monitor for efficacy.
lansoprazole	CYP2C19	What would be the clinical guidance for someone who is Rapid Metabolizer for CYP2C19 with regards to taking lansoprazole?	Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses.Monitor for efficacy.
lansoprazole	CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer for CYP2C19 with regards to taking lansoprazole?	Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses.Monitor for efficacy.
lansoprazole	CYP2C19	What would be the clinical guidance for someone who is Likely Intermediate Metabolizer for CYP2C19 with regards to taking lansoprazole?	Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.
lansoprazole	CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer for CYP2C19 with regards to taking lansoprazole?	Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.
lansoprazole	CYP2C19	What would be the clinical guidance for someone who is Likely Poor Metabolizer for CYP2C19 with regards to taking lansoprazole?	Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.
lansoprazole	CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer for CYP2C19 with regards to taking lansoprazole?	Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.
lansoprazole	CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2C19 with regards to taking lansoprazole?	No recommendation
pantoprazole	CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2C19 with regards to taking pantoprazole?	Increase starting daily dose by 100%. Daily dose may be given in divided doses. Monitor for efficacy.
pantoprazole	CYP2C19	What would be the clinical guidance for someone who is Rapid Metabolizer for CYP2C19 with regards to taking pantoprazole?	Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses.Monitor for efficacy.
pantoprazole	CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer for CYP2C19 with regards to taking pantoprazole?	Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses.Monitor for efficacy.
pantoprazole	CYP2C19	What would be the clinical guidance for someone who is Likely Intermediate Metabolizer for CYP2C19 with regards to taking pantoprazole?	Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.
pantoprazole	CYP2C19	What would be the clinical guidance for someone who is Likely Poor Metabolizer for CYP2C19 with regards to taking pantoprazole?	Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.
pantoprazole	CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer for CYP2C19 with regards to taking pantoprazole?	Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.
pantoprazole	CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2C19 with regards to taking pantoprazole?	No recommendation
ondansetron	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 with regards to taking ondansetron?	Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).
ondansetron	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 with regards to taking ondansetron?	Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).
ondansetron	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 with regards to taking ondansetron?	Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).
ondansetron	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 with regards to taking ondansetron?	Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).
ondansetron	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 with regards to taking ondansetron?	Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).
ondansetron	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 with regards to taking ondansetron?	Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).
ondansetron	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 with regards to taking ondansetron?	Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).
ondansetron	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 with regards to taking ondansetron?	Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).
ondansetron	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 with regards to taking ondansetron?	Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).
ondansetron	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 with regards to taking ondansetron?	Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).
ondansetron	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 with regards to taking ondansetron?	Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).
ondansetron	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 with regards to taking ondansetron?	Initiate therapy with recommended starting dose.
ondansetron	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 with regards to taking ondansetron?	Initiate therapy with recommended starting dose.
ondansetron	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 with regards to taking ondansetron?	Initiate therapy with recommended starting dose.
ondansetron	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 with regards to taking ondansetron?	Initiate therapy with recommended starting dose.
ondansetron	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 with regards to taking ondansetron?	Initiate therapy with recommended starting dose.
ondansetron	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 with regards to taking ondansetron?	Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype. Initiate therapy with recommended starting dose.
ondansetron	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 with regards to taking ondansetron?	Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype. Initiate therapy with recommended starting dose.
ondansetron	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 with regards to taking ondansetron?	Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype. Initiate therapy with recommended starting dose.
ondansetron	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 with regards to taking ondansetron?	Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype. Initiate therapy with recommended starting dose.
ondansetron	CYP2D6	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 with regards to taking ondansetron?	Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype. Initiate therapy with recommended starting dose.
ondansetron	CYP2D6	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 with regards to taking ondansetron?	No recommendation
phenazopyridine	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking phenazopyridine?	No reason to avoid based on G6PD status at standard doses
tropisetron	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 with regards to taking tropisetron?	Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).
tropisetron	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 with regards to taking tropisetron?	Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).
tropisetron	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 with regards to taking tropisetron?	Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).
tropisetron	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 with regards to taking tropisetron?	Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).
tropisetron	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 with regards to taking tropisetron?	Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).
tropisetron	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 with regards to taking tropisetron?	Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).
tropisetron	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 with regards to taking tropisetron?	Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).
tropisetron	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 with regards to taking tropisetron?	Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).
tropisetron	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 with regards to taking tropisetron?	Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).
tropisetron	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 with regards to taking tropisetron?	Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).
tropisetron	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 with regards to taking tropisetron?	Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).
tropisetron	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 with regards to taking tropisetron?	Initiate therapy with recommended starting dose.
tropisetron	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 with regards to taking tropisetron?	Initiate therapy with recommended starting dose.
tropisetron	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 with regards to taking tropisetron?	Initiate therapy with recommended starting dose.
tropisetron	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 with regards to taking tropisetron?	Initiate therapy with recommended starting dose.
tropisetron	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 with regards to taking tropisetron?	Initiate therapy with recommended starting dose.
tropisetron	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 with regards to taking tropisetron?	Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype. Initiate therapy with recommended starting dose.
tropisetron	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 with regards to taking tropisetron?	Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype. Initiate therapy with recommended starting dose.
tropisetron	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 with regards to taking tropisetron?	Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype. Initiate therapy with recommended starting dose.
tropisetron	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 with regards to taking tropisetron?	Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype. Initiate therapy with recommended starting dose.
tropisetron	CYP2D6	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 with regards to taking tropisetron?	Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype. Initiate therapy with recommended starting dose.
tropisetron	CYP2D6	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 with regards to taking tropisetron?	No recommendation
oxcarbazepine	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 negative for HLA-B with regards to taking oxcarbazepine?	Use oxcarbazepine per standard dosing guidelines.
oxcarbazepine	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking oxcarbazepine?	If patient is oxcarbazepine-naïve, do not use oxcarbazepine.
oxcarbazepine	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 negative for HLA-B with regards to taking oxcarbazepine?	Use oxcarbazepine per standard dosing guidelines.
oxcarbazepine	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking oxcarbazepine?	The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (~4-28 days), and cases usually occur within three months of dosing; therefore, if the patient has previously used oxcarbazepine consistently for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of oxcarbazepine in the future.
paroxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 with regards to taking paroxetine?	Select alternative drug not predominantly metabolized by CYP2D6.
paroxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 with regards to taking paroxetine?	Select alternative drug not predominantly metabolized by CYP2D6.
paroxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 with regards to taking paroxetine?	Select alternative drug not predominantly metabolized by CYP2D6.
paroxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 with regards to taking paroxetine?	Select alternative drug not predominantly metabolized by CYP2D6.
paroxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 with regards to taking paroxetine?	Select alternative drug not predominantly metabolized by CYP2D6.
paroxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 with regards to taking paroxetine?	Select alternative drug not predominantly metabolized by CYP2D6.
paroxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 with regards to taking paroxetine?	Select alternative drug not predominantly metabolized by CYP2D6.
paroxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 with regards to taking paroxetine?	Select alternative drug not predominantly metabolized by CYP2D6.
paroxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 with regards to taking paroxetine?	Select alternative drug not predominantly metabolized by CYP2D6.
paroxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 with regards to taking paroxetine?	Select alternative drug not predominantly metabolized by CYP2D6.
phenazopyridine	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking phenazopyridine?	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.
paroxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 with regards to taking paroxetine?	Select alternative drug not predominantly metabolized by CYP2D6.
paroxetine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 with regards to taking paroxetine?	Initiate therapy with recommended starting dose
paroxetine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 with regards to taking paroxetine?	Initiate therapy with recommended starting dose
paroxetine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 with regards to taking paroxetine?	Initiate therapy with recommended starting dose
paroxetine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 with regards to taking paroxetine?	Initiate therapy with recommended starting dose
paroxetine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 with regards to taking paroxetine?	Initiate therapy with recommended starting dose
paroxetine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 with regards to taking paroxetine?	Consider a lower starting dose and slower titration schedule as compared to normal metabolizers.
paroxetine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 with regards to taking paroxetine?	Consider a lower starting dose and slower titration schedule as compared to normal metabolizers.
paroxetine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 with regards to taking paroxetine?	Consider a lower starting dose and slower titration schedule as compared to normal metabolizers.
paroxetine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 with regards to taking paroxetine?	Consider a lower starting dose and slower titration schedule as compared to normal metabolizers.
paroxetine	CYP2D6	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 with regards to taking paroxetine?	Consider a 50% reduction in recommended starting dose, slower titration schedule, and a 50% lower maintenance dose as compared to normal metabolizers.
paroxetine	CYP2D6	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 with regards to taking paroxetine?	No recommendation
phenazopyridine	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking phenazopyridine?	No reason to avoid based on G6PD status
quinine	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking quinine?	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended
quinine	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking quinine?	No reason to avoid based on G6PD status at standard doses
quinine	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking quinine?	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.
sulfadiazine	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking sulfadiazine?	No reason to avoid based on G6PD status
sulfadiazine	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking sulfadiazine?	No reason to avoid based on G6PD status at standard doses
sulfadiazine	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking sulfadiazine?	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended
sulfadiazine	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking sulfadiazine?	No reason to avoid based on G6PD status at standard doses
sulfadiazine	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking sulfadiazine?	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.
sulfadimidine	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking sulfadimidine?	No reason to avoid based on G6PD status
sulfadimidine	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking sulfadimidine?	No reason to avoid based on G6PD status at standard doses
sulfadimidine	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking sulfadimidine?	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended
sulfadimidine	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking sulfadimidine?	No reason to avoid based on G6PD status at standard doses
sulfadimidine	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking sulfadimidine?	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.
sulfamethoxazole / trimethoprim	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking sulfamethoxazole / trimethoprim?	No reason to avoid based on G6PD status
sulfamethoxazole / trimethoprim	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking sulfamethoxazole / trimethoprim?	No reason to avoid based on G6PD status at standard doses
sulfamethoxazole / trimethoprim	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking sulfamethoxazole / trimethoprim?	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended
sulfamethoxazole / trimethoprim	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking sulfamethoxazole / trimethoprim?	No reason to avoid based on G6PD status at standard doses
sulfanilamide	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking sulfanilamide?	No reason to avoid based on G6PD status
sulfanilamide	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking sulfanilamide?	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended
sulfanilamide	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking sulfanilamide?	No reason to avoid based on G6PD status at standard doses
sulfanilamide	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking sulfanilamide?	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.
sulfasalazine	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking sulfasalazine?	No reason to avoid based on G6PD status
sulfasalazine	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking sulfasalazine?	No reason to avoid based on G6PD status at standard doses
sulfasalazine	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking sulfasalazine?	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended
sulfasalazine	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking sulfasalazine?	No reason to avoid based on G6PD status at standard doses
sulfasalazine	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking sulfasalazine?	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.
sulfisoxazole	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking sulfisoxazole?	No reason to avoid based on G6PD status
sulfisoxazole	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking sulfisoxazole?	No reason to avoid based on G6PD status at standard doses
sulfisoxazole	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking sulfisoxazole?	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended
sulfisoxazole	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking sulfisoxazole?	No reason to avoid based on G6PD status at standard doses
sulfisoxazole	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking sulfisoxazole?	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.
tolbutamide	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking tolbutamide?	No reason to avoid based on G6PD status
tolbutamide	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking tolbutamide?	No reason to avoid based on G6PD status at standard doses
tolbutamide	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking tolbutamide?	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended
tolbutamide	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking tolbutamide?	No reason to avoid based on G6PD status at standard doses
tamoxifen	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 with regards to taking tamoxifen?	Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).
phenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 negative for HLA-B with regards to taking phenytoin?	No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.
phenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 negative for HLA-B with regards to taking phenytoin?	For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.
phenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 negative for HLA-B with regards to taking phenytoin?	For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.
phenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 negative for HLA-B with regards to taking phenytoin?	For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.
phenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 negative for HLA-B with regards to taking phenytoin?	No recommendation
phenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking phenytoin?	If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.
phenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking phenytoin?	If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.
phenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking phenytoin?	If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.
phenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking phenytoin?	If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.
phenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking phenytoin?	If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.
phenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking phenytoin?	If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.
phenytoin	HLA-B	What would be the clinical guidance for someone who is No HLA-B Result for HLA-B with regards to taking phenytoin?	No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.
phenytoin	HLA-B	What would be the clinical guidance for someone who is No HLA-B Result for HLA-B with regards to taking phenytoin?	No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.
phenytoin	HLA-B	What would be the clinical guidance for someone who is No HLA-B Result for HLA-B with regards to taking phenytoin?	For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.
phenytoin	HLA-B	What would be the clinical guidance for someone who is No HLA-B Result for HLA-B with regards to taking phenytoin?	For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.
phenytoin	HLA-B	What would be the clinical guidance for someone who is No HLA-B Result for HLA-B with regards to taking phenytoin?	For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.
phenytoin	HLA-B	What would be the clinical guidance for someone who is No HLA-B Result for HLA-B with regards to taking phenytoin?	No recommendation
phenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 negative for HLA-B with regards to taking phenytoin?	No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.
phenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking phenytoin?	If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.
phenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 negative for HLA-B with regards to taking phenytoin?	No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.
phenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 negative for HLA-B with regards to taking phenytoin?	No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.
phenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 negative for HLA-B with regards to taking phenytoin?	For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.
phenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 negative for HLA-B with regards to taking phenytoin?	For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.
phenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 negative for HLA-B with regards to taking phenytoin?	For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.
phenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking phenytoin?	If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.
phenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking phenytoin?	If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.
phenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking phenytoin?	If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.
phenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking phenytoin?	If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.
phenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking phenytoin?	If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.
phenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking phenytoin?	If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.
phenytoin	HLA-B	What would be the clinical guidance for someone who is No HLA-B Result for HLA-B with regards to taking phenytoin?	No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.
phenytoin	HLA-B	What would be the clinical guidance for someone who is No HLA-B Result for HLA-B with regards to taking phenytoin?	No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.
phenytoin	HLA-B	What would be the clinical guidance for someone who is No HLA-B Result for HLA-B with regards to taking phenytoin?	For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.
phenytoin	HLA-B	What would be the clinical guidance for someone who is No HLA-B Result for HLA-B with regards to taking phenytoin?	For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.
phenytoin	HLA-B	What would be the clinical guidance for someone who is No HLA-B Result for HLA-B with regards to taking phenytoin?	For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.
phenytoin	HLA-B	What would be the clinical guidance for someone who is No HLA-B Result for HLA-B with regards to taking phenytoin?	No recommendation
phenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 negative for HLA-B with regards to taking phenytoin?	No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.
phenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking phenytoin?	If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 negative for HLA-B with regards to taking fosphenytoin?	No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 negative for HLA-B with regards to taking fosphenytoin?	No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 negative for HLA-B with regards to taking fosphenytoin?	For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 negative for HLA-B with regards to taking fosphenytoin?	For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 negative for HLA-B with regards to taking fosphenytoin?	For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 negative for HLA-B with regards to taking fosphenytoin?	No recommendation
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking fosphenytoin?	If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking fosphenytoin?	If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.
tamoxifen	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 with regards to taking tamoxifen?	Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking fosphenytoin?	If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking fosphenytoin?	If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking fosphenytoin?	If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking fosphenytoin?	If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is No HLA-B Result for HLA-B with regards to taking fosphenytoin?	No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is No HLA-B Result for HLA-B with regards to taking fosphenytoin?	No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is No HLA-B Result for HLA-B with regards to taking fosphenytoin?	For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is No HLA-B Result for HLA-B with regards to taking fosphenytoin?	For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is No HLA-B Result for HLA-B with regards to taking fosphenytoin?	For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is No HLA-B Result for HLA-B with regards to taking fosphenytoin?	No recommendation
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 negative for HLA-B with regards to taking fosphenytoin?	No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking fosphenytoin?	If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 negative for HLA-B with regards to taking fosphenytoin?	No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 negative for HLA-B with regards to taking fosphenytoin?	No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 negative for HLA-B with regards to taking fosphenytoin?	For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 negative for HLA-B with regards to taking fosphenytoin?	For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 negative for HLA-B with regards to taking fosphenytoin?	For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 negative for HLA-B with regards to taking fosphenytoin?	No recommendation
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking fosphenytoin?	If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking fosphenytoin?	If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking fosphenytoin?	If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking fosphenytoin?	If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer for CYP2B6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking sertraline?	Initiate therapy with recommended starting dose.
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking fosphenytoin?	If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking fosphenytoin?	If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is No HLA-B Result for HLA-B with regards to taking fosphenytoin?	No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is No HLA-B Result for HLA-B with regards to taking fosphenytoin?	No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is No HLA-B Result for HLA-B with regards to taking fosphenytoin?	For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is No HLA-B Result for HLA-B with regards to taking fosphenytoin?	For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is No HLA-B Result for HLA-B with regards to taking fosphenytoin?	For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is No HLA-B Result for HLA-B with regards to taking fosphenytoin?	No recommendation
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 negative for HLA-B with regards to taking fosphenytoin?	No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking fosphenytoin?	If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.
piroxicam	CYP2C9	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2C9 with regards to taking piroxicam?	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.
piroxicam	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.5 for CYP2C9 with regards to taking piroxicam?	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.
piroxicam	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2C9 with regards to taking piroxicam?	Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (see CPIC THERAPEUTIC RECOMMENDATIONS FOR CELECOXIB, FLURBIPROFEN, LORNOXICAM, AND IBUPROFEN BASED ON CYP2C9 PHENOTYPE).
piroxicam	CYP2C9	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.5 for CYP2C9 with regards to taking piroxicam?	Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (see CPIC THERAPEUTIC RECOMMENDATIONS FOR CELECOXIB, FLURBIPROFEN, LORNOXICAM, AND IBUPROFEN BASED ON CYP2C9 PHENOTYPE).
piroxicam	CYP2C9	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2C9 with regards to taking piroxicam?	Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (see CPIC THERAPEUTIC RECOMMENDATIONS FOR CELECOXIB, FLURBIPROFEN, LORNOXICAM, AND IBUPROFEN BASED ON CYP2C9 PHENOTYPE).
piroxicam	CYP2C9	What would be the clinical guidance for someone who is Indeterminate for CYP2C9 with regards to taking piroxicam?	No recommendation
pitavastatin	SLCO1B1	What would be the clinical guidance for someone who is Increased Function for SLCO1B1 with regards to taking pitavastatin?	Prescribe desired starting dose and adjust doses based on disease-specific guidelines.
pitavastatin	SLCO1B1	What would be the clinical guidance for someone who is Normal Function for SLCO1B1 with regards to taking pitavastatin?	Prescribe desired starting dose and adjust doses based on disease-specific guidelines.
pitavastatin	SLCO1B1	What would be the clinical guidance for someone who is Possible Decreased Function for SLCO1B1 with regards to taking pitavastatin?	Prescribe ≤ 2mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >1mg. If dose >2mg needed for desired efficacy, consider an alternative statin (see Figure 1 of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. pitavastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
pitavastatin	SLCO1B1	What would be the clinical guidance for someone who is Decreased Function for SLCO1B1 with regards to taking pitavastatin?	Prescribe ≤ 2mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >1mg. If dose >2mg needed for desired efficacy, consider an alternative statin (see Figure 1 of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. pitavastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
pitavastatin	SLCO1B1	What would be the clinical guidance for someone who is Poor Function for SLCO1B1 with regards to taking pitavastatin?	Prescribe ≤1mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. If dose >1mg needed for desired efficacy, consider an alternative statin (see Figure 1 of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. pitavastatin plus non-statin guideline directed medical therapy)(PMID: 30423391).
pitavastatin	SLCO1B1	What would be the clinical guidance for someone who is Indeterminate for SLCO1B1 with regards to taking pitavastatin?	No recommendation
pravastatin	SLCO1B1	What would be the clinical guidance for someone who is Increased Function for SLCO1B1 with regards to taking pravastatin?	Prescribe desired starting dose and adjust doses based on disease-specific guidelines.
pravastatin	SLCO1B1	What would be the clinical guidance for someone who is Normal Function for SLCO1B1 with regards to taking pravastatin?	Prescribe desired starting dose and adjust doses based on disease-specific guidelines.
tamoxifen	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 with regards to taking tamoxifen?	Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).
pravastatin	SLCO1B1	What would be the clinical guidance for someone who is Possible Decreased Function for SLCO1B1 with regards to taking pravastatin?	Prescribe desired starting dose and adjust doses of pravastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy with pravastatin especially with doses >40mg per day.
pravastatin	SLCO1B1	What would be the clinical guidance for someone who is Decreased Function for SLCO1B1 with regards to taking pravastatin?	Prescribe desired starting dose and adjust doses of pravastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy with pravastatin especially with doses >40mg per day.
pravastatin	SLCO1B1	What would be the clinical guidance for someone who is Poor Function for SLCO1B1 with regards to taking pravastatin?	Prescribe ≤40mg as a starting dose and adjust doses of pravastatin based on disease-specific guidelines. If patient is tolerating 40mg dose but higher potency is needed, a higher dose (>40mg) or an alternative statin (see Figure 1 of of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. pravastatin plus non-statin guideline directed medical therapy)(PMID: 30423391) could be considered. Prescriber should be aware of possible increased risk for myopathy especially with pravastatin doses >40mg.
pravastatin	SLCO1B1	What would be the clinical guidance for someone who is Indeterminate for SLCO1B1 with regards to taking pravastatin?	No recommendation
primaquine	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking primaquine?	No reason to avoid based on G6PD status
primaquine	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking primaquine?	Avoid primaquine, except in the following cases where established expert consensus guidelines for the treatment of malaria should be followed: (1) Treating Plasmodium vivax or Plasmodium ovale malaria for radical cure of liver-stage infections: 0.75 mg/kg once weekly x8 weeks (WHO) or 45 mg once weekly x8 weeks (CDC) - with close monitoring for hemolysis; (2) Treating Plasmodium falciparum malaria by using primaquine single dose as a gametocytocide at 0.25 mg/kg (WHO) - without need for monitoring for hemolysis.
primaquine	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking primaquine?	Avoid primaquine
primaquine	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking primaquine?	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.
primaquine	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking primaquine?	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.
rosuvastatin	ABCG2;SLCO1B1	What would be the clinical guidance for someone who is Poor Function for ABCG2 and Decreased Function for SLCO1B1 with regards to taking rosuvastatin?	Prescribe ≤10mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If dose >10mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., rosuvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
rosuvastatin	ABCG2;SLCO1B1	What would be the clinical guidance for someone who is Poor Function for ABCG2 and Possible Decreased Function for SLCO1B1 with regards to taking rosuvastatin?	Prescribe ≤10mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If dose >10mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., rosuvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
rosuvastatin	ABCG2;SLCO1B1	What would be the clinical guidance for someone who is Poor Function for ABCG2 and Poor Function for SLCO1B1 with regards to taking rosuvastatin?	Prescribe ≤10mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If dose >10mg needed for desired efficacy, consider combination therapy (i.e., rosuvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
rosuvastatin	ABCG2;SLCO1B1	What would be the clinical guidance for someone who is Normal Function for ABCG2 and Poor Function for SLCO1B1 with regards to taking rosuvastatin?	Prescribe ≤20mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If dose > 20mg needed for desired efficacy, consider combination therapy (i.e., rosuvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
rosuvastatin	ABCG2;SLCO1B1	What would be the clinical guidance for someone who is Poor Function for ABCG2 and Increased Function for SLCO1B1 with regards to taking rosuvastatin?	Prescribe ≤20mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., rosuvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
rosuvastatin	ABCG2;SLCO1B1	What would be the clinical guidance for someone who is Poor Function for ABCG2 and Normal Function for SLCO1B1 with regards to taking rosuvastatin?	Prescribe ≤20mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., rosuvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
rosuvastatin	ABCG2;SLCO1B1	What would be the clinical guidance for someone who is Decreased Function for ABCG2 and Poor Function for SLCO1B1 with regards to taking rosuvastatin?	Prescribe ≤20mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If dose >20mg needed for desired efficacy, consider combination therapy (i.e., rosuvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
rosuvastatin	ABCG2;SLCO1B1	What would be the clinical guidance for someone who is Decreased Function for ABCG2 and Increased Function for SLCO1B1 with regards to taking rosuvastatin?	Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines.
rosuvastatin	ABCG2;SLCO1B1	What would be the clinical guidance for someone who is Normal Function for ABCG2 and Increased Function for SLCO1B1 with regards to taking rosuvastatin?	Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines.
rosuvastatin	ABCG2;SLCO1B1	What would be the clinical guidance for someone who is Decreased Function for ABCG2 and Normal Function for SLCO1B1 with regards to taking rosuvastatin?	Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines.
rosuvastatin	ABCG2;SLCO1B1	What would be the clinical guidance for someone who is Normal Function for ABCG2 and Normal Function for SLCO1B1 with regards to taking rosuvastatin?	Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines.
rosuvastatin	ABCG2;SLCO1B1	What would be the clinical guidance for someone who is Decreased Function for ABCG2 and Decreased Function for SLCO1B1 with regards to taking rosuvastatin?	Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >20mg.
rosuvastatin	ABCG2;SLCO1B1	What would be the clinical guidance for someone who is Decreased Function for ABCG2 and Possible Decreased Function for SLCO1B1 with regards to taking rosuvastatin?	Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >20mg.
rosuvastatin	ABCG2;SLCO1B1	What would be the clinical guidance for someone who is Normal Function for ABCG2 and Decreased Function for SLCO1B1 with regards to taking rosuvastatin?	Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >20mg.
rosuvastatin	ABCG2;SLCO1B1	What would be the clinical guidance for someone who is Normal Function for ABCG2 and Possible Decreased Function for SLCO1B1 with regards to taking rosuvastatin?	Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >20mg.
rosuvastatin	ABCG2;SLCO1B1	What would be the clinical guidance for someone who is No Result for ABCG2 and Decreased Function for SLCO1B1 with regards to taking rosuvastatin?	Based on SLCO1B1 status, prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >20mg. ABCG2 genotype result is not available.
rosuvastatin	ABCG2;SLCO1B1	What would be the clinical guidance for someone who is No Result for ABCG2 and Increased Function for SLCO1B1 with regards to taking rosuvastatin?	Based on SLCO1B1 status, prescribe desired starting dose and adjust doses based on disease-specific guidelines. ABCG2 genotype result is not available.
rosuvastatin	ABCG2;SLCO1B1	What would be the clinical guidance for someone who is Decreased Function for ABCG2 and Indeterminate for SLCO1B1 with regards to taking rosuvastatin?	Based on ABCG2 status, prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific guidelines and specific population guidelines. SLCO1B1 phenotype could not be assigned based on genotyping.
rosuvastatin	ABCG2;SLCO1B1	What would be the clinical guidance for someone who is No Result for ABCG2 and Indeterminate for SLCO1B1 with regards to taking rosuvastatin?	n/a
rosuvastatin	ABCG2;SLCO1B1	What would be the clinical guidance for someone who is Normal Function for ABCG2 and Indeterminate for SLCO1B1 with regards to taking rosuvastatin?	Based on ABCG2 status, prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. SLCO1B1 phenotype could not be assigned based on genotyping.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Rapid Metabolizer for CYP2B6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking sertraline?	Initiate therapy with recommended starting dose. If patient does not adequately respond to recommended maintenance dosing, consider titrating to a highermaintenance dose or switching to a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19 or CYP2B6.
rosuvastatin	ABCG2;SLCO1B1	What would be the clinical guidance for someone who is Poor Function for ABCG2 and Indeterminate for SLCO1B1 with regards to taking rosuvastatin?	Based on ABCG2 status, prescribe ≤20mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., rosuvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391). SLCO1B1 phenotype could not be assigned based on genotyping.
rosuvastatin	ABCG2;SLCO1B1	What would be the clinical guidance for someone who is Decreased Function for ABCG2 and No Result for SLCO1B1 with regards to taking rosuvastatin?	Based on ABCG2 status, prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific guidelines and specific population guidelines. SLCO1B1 genotype result is not available.
rosuvastatin	ABCG2;SLCO1B1	What would be the clinical guidance for someone who is Normal Function for ABCG2 and No Result for SLCO1B1 with regards to taking rosuvastatin?	Based on ABCG2 status, prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. SLCO1B1 genotype result is not available.
rosuvastatin	ABCG2;SLCO1B1	What would be the clinical guidance for someone who is Poor Function for ABCG2 and No Result for SLCO1B1 with regards to taking rosuvastatin?	Based on ABCG2 status, prescribe ≤20mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., rosuvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391). SLCO1B1 genotype result is not available.
rosuvastatin	ABCG2;SLCO1B1	What would be the clinical guidance for someone who is No Result for ABCG2 and Normal Function for SLCO1B1 with regards to taking rosuvastatin?	Based on SLCO1B1 status, prescribe desired starting dose and adjust doses based on disease-specific guidelines. ABCG2 genotype result is not available.
rosuvastatin	ABCG2;SLCO1B1	What would be the clinical guidance for someone who is No Result for ABCG2 and Poor Function for SLCO1B1 with regards to taking rosuvastatin?	Based on SLCO1B1 status, prescribe ≤20mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines If dose >20mg needed for desired efficacy, consider combination therapy (i.e. rosuvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391). ABCG2 genotype result is not available.
rosuvastatin	ABCG2;SLCO1B1	What would be the clinical guidance for someone who is No Result for ABCG2 and Possible Decreased Function for SLCO1B1 with regards to taking rosuvastatin?	Based on SLCO1B1 status, prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >20mg. ABCG2 genotype result is not available.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is No Result for CYP2B6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking sertraline?	Initiate therapy with recommended starting dose.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2B6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking sertraline?	Initiate therapy with recommended starting dose. If patient does not adequately respond to recommended maintenance dosing, consider titrating to a highermaintenance dose or switching to a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19 or CYP2B6.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer for CYP2B6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking sertraline?	Initiate therapy with recommended starting dose.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is No Result for CYP2B6 and Rapid Metabolizer for CYP2C19 with regards to taking sertraline?	Initiate therapy with recommended starting dose.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2B6 and Rapid Metabolizer for CYP2C19 with regards to taking sertraline?	Initiate therapy with recommended starting dose. If patient does not adequately respond to recommended maintenance dosing, consider titrating to a highermaintenance dose or switching to a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19 or CYP2B6.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Rapid Metabolizer for CYP2B6 and Rapid Metabolizer for CYP2C19 with regards to taking sertraline?	Initiate therapy with recommended starting dose. If patient does not adequately respond to recommended maintenance dosing, consider titrating to a highermaintenance dose or switching to a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19 or CYP2B6.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer for CYP2B6 and Rapid Metabolizer for CYP2C19 with regards to taking sertraline?	Initiate therapy with recommended starting dose.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer for CYP2B6 and Rapid Metabolizer for CYP2C19 with regards to taking sertraline?	Initiate therapy with recommended starting dose.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer for CYP2B6 and Rapid Metabolizer for CYP2C19 with regards to taking sertraline?	Initiate therapy with recommended starting dose.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2B6 and Rapid Metabolizer for CYP2C19 with regards to taking sertraline?	Initiate therapy with recommended starting dose.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is No Result for CYP2B6 and Normal Metabolizer for CYP2C19 with regards to taking sertraline?	Initiate therapy with recommended starting dose
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2B6 and Normal Metabolizer for CYP2C19 with regards to taking sertraline?	Initiate therapy with recommended starting dose.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Rapid Metabolizer for CYP2B6 and Normal Metabolizer for CYP2C19 with regards to taking sertraline?	Initiate therapy with recommended starting dose.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer for CYP2B6 and Normal Metabolizer for CYP2C19 with regards to taking sertraline?	Initiate therapy with recommended starting dose.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer for CYP2B6 and Normal Metabolizer for CYP2C19 with regards to taking sertraline?	Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer for CYP2B6 and Normal Metabolizer for CYP2C19 with regards to taking sertraline?	Consider a lower starting dose, slower titration schedule and 25% reduction of standard maintenance dose as compared to CYP2B6 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2B6.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2B6 and Normal Metabolizer for CYP2C19 with regards to taking sertraline?	Initiate therapy with recommended starting dose.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is No Result for CYP2B6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking sertraline?	Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose than normal metabolizers.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2B6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking sertraline?	Initiate therapy with recommended starting dose.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Rapid Metabolizer for CYP2B6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking sertraline?	Initiate therapy with recommended starting dose.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer for CYP2B6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking sertraline?	Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer for CYP2B6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking sertraline?	Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose than normal metabolizers.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer for CYP2B6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking sertraline?	Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2B6 normal metabolizers
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2B6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking sertraline?	Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is No Result for CYP2B6 and Intermediate Metabolizer for CYP2C19 with regards to taking sertraline?	Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose than CYP2C19 normal metabolizers.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2B6 and Intermediate Metabolizer for CYP2C19 with regards to taking sertraline?	Initiate therapy with recommended starting dose.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Rapid Metabolizer for CYP2B6 and Intermediate Metabolizer for CYP2C19 with regards to taking sertraline?	Initiate therapy with recommended starting dose.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer for CYP2B6 and Intermediate Metabolizer for CYP2C19 with regards to taking sertraline?	Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer for CYP2B6 and Intermediate Metabolizer for CYP2C19 with regards to taking sertraline?	Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose than normal metabolizers.
tamoxifen	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 with regards to taking tamoxifen?	Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer for CYP2B6 and Intermediate Metabolizer for CYP2C19 with regards to taking sertraline?	Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2B6 normal metabolizers
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2B6 and Intermediate Metabolizer for CYP2C19 with regards to taking sertraline?	Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is No Result for CYP2B6 and Likely Poor Metabolizer for CYP2C19 with regards to taking sertraline?	Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2B6 and Likely Poor Metabolizer for CYP2C19 with regards to taking sertraline?	Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Rapid Metabolizer for CYP2B6 and Likely Poor Metabolizer for CYP2C19 with regards to taking sertraline?	Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer for CYP2B6 and Likely Poor Metabolizer for CYP2C19 with regards to taking sertraline?	Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer for CYP2B6 and Likely Poor Metabolizer for CYP2C19 with regards to taking sertraline?	Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer for CYP2B6 and Likely Poor Metabolizer for CYP2C19 with regards to taking sertraline?	Select an alternative antidepressant not primarily metabolized by CYP2C19 or CYP2B6.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2B6 and Likely Poor Metabolizer for CYP2C19 with regards to taking sertraline?	Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is No Result for CYP2B6 and Poor Metabolizer for CYP2C19 with regards to taking sertraline?	Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2B6 and Poor Metabolizer for CYP2C19 with regards to taking sertraline?	Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Rapid Metabolizer for CYP2B6 and Poor Metabolizer for CYP2C19 with regards to taking sertraline?	Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer for CYP2B6 and Poor Metabolizer for CYP2C19 with regards to taking sertraline?	Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer for CYP2B6 and Poor Metabolizer for CYP2C19 with regards to taking sertraline?	Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer for CYP2B6 and Poor Metabolizer for CYP2C19 with regards to taking sertraline?	Select an alternative antidepressant not primarily metabolized by CYP2C19 or CYP2B6.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2B6 and Poor Metabolizer for CYP2C19 with regards to taking sertraline?	Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is No Result for CYP2B6 and Indeterminate for CYP2C19 with regards to taking sertraline?	No recommendation
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2B6 and Indeterminate for CYP2C19 with regards to taking sertraline?	Initiate therapy with recommended starting dose.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Rapid Metabolizer for CYP2B6 and Indeterminate for CYP2C19 with regards to taking sertraline?	Initiate therapy with recommended starting dose.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer for CYP2B6 and Indeterminate for CYP2C19 with regards to taking sertraline?	Initiate therapy with recommended starting dose.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer for CYP2B6 and Indeterminate for CYP2C19 with regards to taking sertraline?	Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer for CYP2B6 and Indeterminate for CYP2C19 with regards to taking sertraline?	Consider a lower starting dose, slower titration schedule and 25% reduction of standard maintenance dose as CYP2B6 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2B6.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2B6 and No Result for CYP2C19 with regards to taking sertraline?	Initiate therapy with recommended starting dose.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Rapid Metabolizer for CYP2B6 and No Result for CYP2C19 with regards to taking sertraline?	Initiate therapy with recommended starting dose.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer for CYP2B6 and No Result for CYP2C19 with regards to taking sertraline?	Initiate therapy with recommended starting dose.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer for CYP2B6 and No Result for CYP2C19 with regards to taking sertraline?	Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose than CYP2B6 normal metabolizers.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer for CYP2B6 and No Result for CYP2C19 with regards to taking sertraline?	Consider a lower starting dose, slower titration schedule and 25% reduction of standard maintenance dose as compared to CYP2B6 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2B6.
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2B6 and No Result for CYP2C19 with regards to taking sertraline?	No recommendation
simvastatin	SLCO1B1	What would be the clinical guidance for someone who is Increased Function for SLCO1B1 with regards to taking simvastatin?	Prescribe desired starting dose and adjust doses based on disease-specific guidelines.
simvastatin	SLCO1B1	What would be the clinical guidance for someone who is Normal Function for SLCO1B1 with regards to taking simvastatin?	Prescribe desired starting dose and adjust doses based on disease-specific guidelines.
simvastatin	SLCO1B1	What would be the clinical guidance for someone who is Possible Decreased Function for SLCO1B1 with regards to taking simvastatin?	Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If simvastatin therapy is warranted, limit dose to <20mg/day.
simvastatin	SLCO1B1	What would be the clinical guidance for someone who is Decreased Function for SLCO1B1 with regards to taking simvastatin?	Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If simvastatin therapy is warranted, limit dose to <20mg/day.
simvastatin	SLCO1B1	What would be the clinical guidance for someone who is Poor Function for SLCO1B1 with regards to taking simvastatin?	Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins).
simvastatin	SLCO1B1	What would be the clinical guidance for someone who is Indeterminate for SLCO1B1 with regards to taking simvastatin?	No recommendation
tamoxifen	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 with regards to taking tamoxifen?	Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).
tamoxifen	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 with regards to taking tamoxifen?	Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).
tamoxifen	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 with regards to taking tamoxifen?	Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).
tacrolimus	CYP3A5	What would be the clinical guidance for someone who is Normal Metabolizer for CYP3A5 with regards to taking tacrolimus?	Increase starting dose 1.5 to 2 times recommended starting dose. Total starting dose should not exceed 0.3 mg/kg/day. Use therapeutic drug monitoring to guide dose adjustments.
tacrolimus	CYP3A5	What would be the clinical guidance for someone who is Possible Intermediate Metabolizer for CYP3A5 with regards to taking tacrolimus?	Increase starting dose 1.5 to 2 times recommended starting dose. Total starting dose should not exceed 0.3 mg/kg/day. Use therapeutic drug monitoring to guide dose adjustments.
tacrolimus	CYP3A5	What would be the clinical guidance for someone who is Intermediate Metabolizer for CYP3A5 with regards to taking tacrolimus?	Increase starting dose 1.5 to 2 times recommended starting dose. Total starting dose should not exceed 0.3 mg/kg/day. Use therapeutic drug monitoring to guide dose adjustments.
tacrolimus	CYP3A5	What would be the clinical guidance for someone who is Poor Metabolizer for CYP3A5 with regards to taking tacrolimus?	Initiate therapy with standard recommended dose. Use therapeutic drug monitoring to guide dose adjustments.
tacrolimus	CYP3A5	What would be the clinical guidance for someone who is Indeterminate for CYP3A5 with regards to taking tacrolimus?	No recommendation
tafenoquine	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking tafenoquine?	No reason to avoid based on G6PD status
tafenoquine	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking tafenoquine?	Avoid use
tafenoquine	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking tafenoquine?	Avoid use
tafenoquine	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking tafenoquine?	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.
tafenoquine	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking tafenoquine?	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.
tamoxifen	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 with regards to taking tamoxifen?	Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).
tamoxifen	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 with regards to taking tamoxifen?	Consider hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women, given that these approaches are superior to tamoxifen regardless of CYP2D6 genotype (PMID 26211827). If aromatase inhibitor use is contraindicated, consideration should be given to use a higher but FDA approved tamoxifen dose (40 mg/day)(PMID 27226358). Avoid CYP2D6 strong to weak inhibitors.
tamoxifen	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 with regards to taking tamoxifen?	Consider hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women, given that these approaches are superior to tamoxifen regardless of CYP2D6 genotype (PMID 26211827). If aromatase inhibitor use is contraindicated, consideration should be given to use a higher but FDA approved tamoxifen dose (40 mg/day)(PMID 27226358). Avoid CYP2D6 strong to weak inhibitors.
tamoxifen	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 with regards to taking tamoxifen?	Consider hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women, given that these approaches are superior to tamoxifen regardless of CYP2D6 genotype (PMID 26211827). If aromatase inhibitor use is contraindicated, consideration should be given to use a higher but FDA approved tamoxifen dose (40 mg/day)(PMID 27226358). Avoid CYP2D6 strong to weak inhibitors.
tamoxifen	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 with regards to taking tamoxifen?	Consider hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women, given that these approaches are superior to tamoxifen regardless of CYP2D6 genotype (PMID 26211827). If aromatase inhibitor use is contraindicated, consideration should be given to use a higher but FDA approved tamoxifen dose (40 mg/day)(PMID 27226358). Avoid CYP2D6 strong to weak inhibitors.
tamoxifen	CYP2D6	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 with regards to taking tamoxifen?	Recommend alternative hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women given that these approaches are superior to tamoxifen regardless of CYP2D6 genotype (PMID 26211827) and based on knowledge that CYP2D6 poor metabolizers switched from tamoxifen to anastrozole do not have an increased risk of recurrence (PMID 23213055). Note, higher dose tamoxifen (40 mg/day) increases but does not normalize endoxifen concentrations and can be considered if there are contraindications to aromatase inhibitor therapy (PMID 27226358, 21768473).
tamoxifen	CYP2D6	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 with regards to taking tamoxifen?	No recommendation
tenoxicam	CYP2C9	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2C9 with regards to taking tenoxicam?	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.
tenoxicam	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.5 for CYP2C9 with regards to taking tenoxicam?	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.
tenoxicam	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2C9 with regards to taking tenoxicam?	Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (see CPIC THERAPEUTIC RECOMMENDATIONS FOR CELECOXIB, FLURBIPROFEN, LORNOXICAM, AND IBUPROFEN BASED ON CYP2C9 PHENOTYPE).
tenoxicam	CYP2C9	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.5 for CYP2C9 with regards to taking tenoxicam?	Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (see CPIC THERAPEUTIC RECOMMENDATIONS FOR CELECOXIB, FLURBIPROFEN, LORNOXICAM, AND IBUPROFEN BASED ON CYP2C9 PHENOTYPE).
tenoxicam	CYP2C9	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2C9 with regards to taking tenoxicam?	Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (see CPIC THERAPEUTIC RECOMMENDATIONS FOR CELECOXIB, FLURBIPROFEN, LORNOXICAM, AND IBUPROFEN BASED ON CYP2C9 PHENOTYPE).
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is Indeterminate for TPMT and Indeterminate for NUDT15 with regards to taking thioguanine?	Neither TPMT or NUDT15 phenotype could be assigned based on genotyping performed. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is Indeterminate for TPMT and Intermediate Metabolizer for NUDT15 with regards to taking thioguanine?	Based on NUDT15, start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857). TPMT phenotype could not be assigned based on genotyping performed. Consider evaluating erythrocyte TPMT activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is Indeterminate for TPMT and Normal Metabolizer for NUDT15 with regards to taking thioguanine?	Based on NUDT15, start with normal starting dose (e.g., 40-60 mg/m2/day) and adjust doses of thioguanine and of other myelosuppressive therapy without any special emphasis on thioguanine. Allow 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11037857). However, TPMT phenotype could not be assigned based on genotyping performed. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is Indeterminate for TPMT and Poor Metabolizer for NUDT15 with regards to taking thioguanine?	Based on NUDT15, reduce starting doses to 25% of normal dose and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. In setting of myelosuppression, emphasis should be on reducing thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201). TPMT phenotype could not be assigned based on genotyping performed. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is Indeterminate for TPMT and Possible Intermediate Metabolizer for NUDT15 with regards to taking thioguanine?	Based on NUDT15, start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857). TPMT phenotype could not be assigned based on genotyping performed. Consider evaluating erythrocyte TPMT activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is Indeterminate for TPMT and No Result for NUDT15 with regards to taking thioguanine?	TPMT phenotype could not be assigned based on genotyping performed and NUDT15 genotype is not available. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is No Result for TPMT and Indeterminate for NUDT15 with regards to taking thioguanine?	NUDT15 phenotype could not be assigned based on genotyping performed and there is no TPMT genotype available. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.
tramadol	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 with regards to taking tramadol?	Use tramadol label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider non-codeine opioid.
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is No Result for TPMT and Intermediate Metabolizer for NUDT15 with regards to taking thioguanine?	Based on NUDT15, start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857). TPMT genotype is not available. Consider evaluating erythrocyte TPMT activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is No Result for TPMT and Normal Metabolizer for NUDT15 with regards to taking thioguanine?	Based on NUDT15, start with normal starting dose (e.g., 40-60 mg/m2/day) and adjust doses of thioguanine and of other myelosuppressive therapy without any special emphasis on thioguanine. Allow 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11037857). However, TPMT genotype is not available. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is No Result for TPMT and Poor Metabolizer for NUDT15 with regards to taking thioguanine?	Based on NUDT15, reduce starting doses to 25% of normal dose and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. In setting of myelosuppression, emphasis should be on reducing thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201). TPMT genotype is not available. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is No Result for TPMT and Possible Intermediate Metabolizer for NUDT15 with regards to taking thioguanine?	Based on NUDT15, start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857). TPMT genotype is not available. Consider evaluating erythrocyte TPMT activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is Possible Intermediate Metabolizer for TPMT and Indeterminate for NUDT15 with regards to taking thioguanine?	Based on TPMT status, start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857). NUDT15 phenotype could not be assigned based on genotyping. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is Possible Intermediate Metabolizer for TPMT and Intermediate Metabolizer for NUDT15 with regards to taking thioguanine?	Start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857).
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is Possible Intermediate Metabolizer for TPMT and Normal Metabolizer for NUDT15 with regards to taking thioguanine?	Start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857).
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is Possible Intermediate Metabolizer for TPMT and Poor Metabolizer for NUDT15 with regards to taking thioguanine?	Reduce starting doses to 25% of normal dose and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. In setting of myelosuppression, emphasis should be on reducing thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201).
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is Possible Intermediate Metabolizer for TPMT and Possible Intermediate Metabolizer for NUDT15 with regards to taking thioguanine?	Start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857).
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is Possible Intermediate Metabolizer for TPMT and No Result for NUDT15 with regards to taking thioguanine?	Based on TPMT status, start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857). NUDT15 genotype is not available. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is Intermediate Metabolizer for TPMT and Indeterminate for NUDT15 with regards to taking thioguanine?	Based on TPMT status, start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857). NUDT15 phenotype could not be assigned based on genotyping. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity.
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is Intermediate Metabolizer for TPMT and Intermediate Metabolizer for NUDT15 with regards to taking thioguanine?	Start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857).
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is Intermediate Metabolizer for TPMT and Normal Metabolizer for NUDT15 with regards to taking thioguanine?	Start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857).
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is Intermediate Metabolizer for TPMT and Poor Metabolizer for NUDT15 with regards to taking thioguanine?	Reduce starting doses to 25% of normal dose and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. In setting of myelosuppression, emphasis should be on reducing thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201).
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is Intermediate Metabolizer for TPMT and Possible Intermediate Metabolizer for NUDT15 with regards to taking thioguanine?	Start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857).
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is Intermediate Metabolizer for TPMT and No Result for NUDT15 with regards to taking thioguanine?	Based on TPMT status, start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857). NUDT15 genotype is not available. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity.
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is Normal Metabolizer for TPMT and Indeterminate for NUDT15 with regards to taking thioguanine?	Based on TPMT status, start with normal starting dose (e.g., 40-60 mg/m2/day) and adjust doses of thioguanine and of other myelosuppressive therapy without any special emphasis on thioguanine. Allow 2 weeks to reach steady-state after each dose adjustment (PMID 203542+J1301, 11037857). NUDT15 status could not be determined based on genotyping. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity.
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is Normal Metabolizer for TPMT and Intermediate Metabolizer for NUDT15 with regards to taking thioguanine?	Start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857).
tramadol	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 with regards to taking tramadol?	Use tramadol label recommended age- or weight-specific dosing.
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is Normal Metabolizer for TPMT and Normal Metabolizer for NUDT15 with regards to taking thioguanine?	Start with normal starting dose (e.g., 40-60 mg/m2/day) and adjust doses of thioguanine and of other myelosuppressive therapy without any special emphasis on thioguanine. Allow 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11037857).
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is Normal Metabolizer for TPMT and Poor Metabolizer for NUDT15 with regards to taking thioguanine?	Reduce starting doses to 25% of normal dose and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. In setting of myelosuppression, emphasis should be on reducing thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201).
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is Normal Metabolizer for TPMT and Possible Intermediate Metabolizer for NUDT15 with regards to taking thioguanine?	Start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857).
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is Normal Metabolizer for TPMT and No Result for NUDT15 with regards to taking thioguanine?	Based on TPMT status, start with normal starting dose (e.g., 40-60 mg/m2/day) and adjust doses of thioguanine and of other myelosuppressive therapy without any special emphasis on thioguanine. Allow 2 weeks to reach steady-state after each dose adjustment (PMID 203542+J1301, 11037857). NUDT15 genotype is not available. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity.
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is Poor Metabolizer for TPMT and Indeterminate for NUDT15 with regards to taking thioguanine?	Based on TPMT status, start with drastically reduced doses (PMID 11037857) (reduce daily dose by 10-fold and dose thrice weekly instead of daily) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201). NUDT15 status could not be determined based on genotyping. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity.
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is Poor Metabolizer for TPMT and Intermediate Metabolizer for NUDT15 with regards to taking thioguanine?	Start with drastically reduced doses (PMID 11037857) (reduce daily dose by 10-fold and dose thrice weekly instead of daily) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201).
tramadol	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 with regards to taking tramadol?	Use tramadol label recommended age- or weight-specific dosing.
tramadol	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 with regards to taking tramadol?	Use tramadol label recommended age- or weight-specific dosing.
tramadol	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 with regards to taking tramadol?	Use tramadol label recommended age- or weight-specific dosing.
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is Poor Metabolizer for TPMT and Normal Metabolizer for NUDT15 with regards to taking thioguanine?	Start with drastically reduced doses (PMID 11037857) (reduce daily dose by 10-fold and dose thrice weekly instead of daily) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201).
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is Poor Metabolizer for TPMT and Poor Metabolizer for NUDT15 with regards to taking thioguanine?	Start with drastically reduced doses (PMID 11037857) (reduce daily dose by 10-fold and dose thrice weekly instead of daily) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201).
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is Poor Metabolizer for TPMT and Possible Intermediate Metabolizer for NUDT15 with regards to taking thioguanine?	Start with drastically reduced doses (PMID 11037857) (reduce daily dose by 10-fold and dose thrice weekly instead of daily) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201).
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is Poor Metabolizer for TPMT and No Result for NUDT15 with regards to taking thioguanine?	Based on TPMT status, start with drastically reduced doses (PMID 11037857) (reduce daily dose by 10-fold and dose thrice weekly instead of daily) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201). NUDT15 genotype is not available. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity.
toluidine blue	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking toluidine blue?	No reason to avoid ased on G6PD status
toluidine blue	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking toluidine blue?	Avoid use
toluidine blue	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking toluidine blue?	Avoid use
toluidine blue	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking toluidine blue?	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.
toluidine blue	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking toluidine blue?	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.
tramadol	CYP2D6	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 with regards to taking tramadol?	No recommendation
tramadol	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 with regards to taking tramadol?	Use tramadol label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider non-codeine opioid.
tramadol	CYP2D6	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 with regards to taking tramadol?	Avoid tramadol use because of possibility of diminished analgesia. If opioid use is warranted, consider a non-codeine opioid.
tramadol	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 with regards to taking tramadol?	Avoid tramadol use because of potential for toxicity. If opioid use is warranted, consider a non-codeine opioid.
tramadol	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 with regards to taking tramadol?	Avoid tramadol use because of potential for toxicity. If opioid use is warranted, consider a non-codeine opioid.
tramadol	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 with regards to taking tramadol?	Avoid tramadol use because of potential for toxicity. If opioid use is warranted, consider a non-codeine opioid.
tramadol	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 with regards to taking tramadol?	Avoid tramadol use because of potential for toxicity. If opioid use is warranted, consider a non-codeine opioid.
tramadol	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 with regards to taking tramadol?	Avoid tramadol use because of potential for toxicity. If opioid use is warranted, consider a non-codeine opioid.
tramadol	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 with regards to taking tramadol?	Avoid tramadol use because of potential for toxicity. If opioid use is warranted, consider a non-codeine opioid.
tramadol	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 with regards to taking tramadol?	Avoid tramadol use because of potential for toxicity. If opioid use is warranted, consider a non-codeine opioid.
tramadol	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 with regards to taking tramadol?	Avoid tramadol use because of potential for toxicity. If opioid use is warranted, consider a non-codeine opioid.
tramadol	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 with regards to taking tramadol?	Avoid tramadol use because of potential for toxicity. If opioid use is warranted, consider a non-codeine opioid.
tramadol	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 with regards to taking tramadol?	Avoid tramadol use because of potential for toxicity. If opioid use is warranted, consider a non-codeine opioid.
tramadol	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 with regards to taking tramadol?	Avoid tramadol use because of potential for toxicity. If opioid use is warranted, consider a non-codeine opioid.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
vortioxetine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 with regards to taking vortioxetine?	Initiate therapy with recommended starting dose.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking trimipramine?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking trimipramine?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking trimipramine?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking trimipramine?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking trimipramine?	Initiate therapy with recommended starting dose.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	Initiate therapy with recommended starting dose.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking trimipramine?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking trimipramine?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking trimipramine?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking trimipramine?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and No Result for CYP2C19 with regards to taking trimipramine?	Initiate therapy with recommended starting dose.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and No Result for CYP2C19 with regards to taking trimipramine?	Initiate therapy with recommended starting dose.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and No Result for CYP2C19 with regards to taking trimipramine?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and No Result for CYP2C19 with regards to taking trimipramine?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and No Result for CYP2C19 with regards to taking trimipramine?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and No Result for CYP2C19 with regards to taking trimipramine?	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	Initiate therapy with recommended starting dose.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	Initiate therapy with recommended starting dose.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	Initiate therapy with recommended starting dose.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	Initiate therapy with recommended starting dose.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	Initiate therapy with recommended starting dose.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking trimipramine?	Initiate therapy with recommended starting dose.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking trimipramine?	Initiate therapy with recommended starting dose.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking trimipramine?	Initiate therapy with recommended starting dose.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking trimipramine?	Initiate therapy with recommended starting dose.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use. If trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use. If trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use. If trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use. If trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use. If trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking trimipramine?	No recommendation
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking trimipramine?	No recommendation
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking trimipramine?	No recommendation
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking trimipramine?	No recommendation
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking trimipramine?	No recommendation
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	Initiate therapy with recommended starting dose.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	Initiate therapy with recommended starting dose.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	Initiate therapy with recommended starting dose.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	Initiate therapy with recommended starting dose.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use. If trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use. If trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use. If trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use. If trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use. If trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and No Result for CYP2C19 with regards to taking trimipramine?	Initiate therapy with recommended starting dose.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and No Result for CYP2C19 with regards to taking trimipramine?	Initiate therapy with recommended starting dose.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and No Result for CYP2C19 with regards to taking trimipramine?	Initiate therapy with recommended starting dose.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use. If a trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use. If a trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking trimipramine?	Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use. If a trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and No Result for CYP2C19 with regards to taking trimipramine?	Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
vortioxetine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 with regards to taking vortioxetine?	Initiate therapy with recommended starting dose.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking trimipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking trimipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking trimipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking trimipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking trimipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking trimipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking trimipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
venlafaxine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 with regards to taking venlafaxine?	No action recommended based on genotype for venlafaxine because of minimal evidence regarding the impact on efficacy or side effects.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking trimipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking trimipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking trimipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking trimipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
voriconazole	CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2C19 with regards to taking voriconazole?	No recommendation
vortioxetine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 with regards to taking vortioxetine?	Initiate therapy with recommended starting dose.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and No Result for CYP2C19 with regards to taking trimipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and No Result for CYP2C19 with regards to taking trimipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking trimipramine?	No recommendation
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 and No Result for CYP2C19 with regards to taking trimipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 and No Result for CYP2C19 with regards to taking trimipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and No Result for CYP2C19 with regards to taking trimipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and No Result for CYP2C19 with regards to taking trimipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and No Result for CYP2C19 with regards to taking trimipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and No Result for CYP2C19 with regards to taking trimipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and No Result for CYP2C19 with regards to taking trimipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and No Result for CYP2C19 with regards to taking trimipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 and No Result for CYP2C19 with regards to taking trimipramine?	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	No recommendation
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and Indeterminate for CYP2C19 with regards to taking trimipramine?	No recommendation
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	No recommendation
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and No Result for CYP2C19 with regards to taking trimipramine?	No recommendation
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	Initiate therapy with recommended starting dose.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking trimipramine?	Initiate therapy with recommended starting dose.
venlafaxine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 with regards to taking venlafaxine?	No action recommended based on genotype for venlafaxine because of minimal evidence regarding the impact on efficacy or side effects.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Indeterminate for CYP2C19 with regards to taking trimipramine?	No recommendation
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine?	Initiate therapy with recommended starting dose.
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking trimipramine?	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
venlafaxine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 with regards to taking venlafaxine?	No action recommended based on genotype for venlafaxine because of minimal evidence regarding the impact on efficacy or side effects.
venlafaxine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 with regards to taking venlafaxine?	No action recommended based on genotype for venlafaxine because of minimal evidence regarding the impact on efficacy or side effects.
venlafaxine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 with regards to taking venlafaxine?	No action recommended based on genotype for venlafaxine because of minimal evidence regarding the impact on efficacy or side effects.
venlafaxine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 with regards to taking venlafaxine?	No action recommended based on genotype for venlafaxine because of minimal evidence regarding the impact on efficacy or side effects.
venlafaxine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 with regards to taking venlafaxine?	No action recommended based on genotype for venlafaxine because of minimal evidence regarding the impact on efficacy or side effects.
venlafaxine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 with regards to taking venlafaxine?	No action recommended based on genotype for venlafaxine because of minimal evidence regarding the impact on efficacy or side effects.
venlafaxine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 with regards to taking venlafaxine?	No action recommended based on genotype for venlafaxine because of minimal evidence regarding the impact on efficacy or side effects.
venlafaxine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 with regards to taking venlafaxine?	No action recommended based on genotype for venlafaxine because of minimal evidence regarding the impact on efficacy or side effects.
venlafaxine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 with regards to taking venlafaxine?	No action recommended based on genotype for venlafaxine because of minimal evidence regarding the impact on efficacy or side effects.
venlafaxine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 with regards to taking venlafaxine?	Initiate therapy with recommended starting dose.
venlafaxine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 with regards to taking venlafaxine?	Initiate therapy with recommended starting dose.
venlafaxine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 with regards to taking venlafaxine?	Initiate therapy with recommended starting dose.
venlafaxine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 with regards to taking venlafaxine?	Initiate therapy with recommended starting dose.
venlafaxine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 with regards to taking venlafaxine?	Initiate therapy with recommended starting dose.
venlafaxine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 with regards to taking venlafaxine?	No action recommended based on genotype for venlafaxine because of minimal evidence regarding the impact on efficacy or side effects.
venlafaxine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 with regards to taking venlafaxine?	No action recommended based on genotype for venlafaxine because of minimal evidence regarding the impact on efficacy or side effects.
venlafaxine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 with regards to taking venlafaxine?	No action recommended based on genotype for venlafaxine because of minimal evidence regarding the impact on efficacy or side effects.
vortioxetine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 with regards to taking vortioxetine?	Initiate therapy with recommended starting dose.
vortioxetine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 with regards to taking vortioxetine?	Initiate therapy with recommended starting dose.
venlafaxine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 with regards to taking venlafaxine?	No action recommended based on genotype for venlafaxine because of minimal evidence regarding the impact on efficacy or side effects.
venlafaxine	CYP2D6	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 with regards to taking venlafaxine?	Consider a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2D6.
venlafaxine	CYP2D6	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 with regards to taking venlafaxine?	No recommendation
voriconazole	CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2C19 with regards to taking voriconazole?	Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include liposomal amphotericin B and posaconazole.
voriconazole	CYP2C19	What would be the clinical guidance for someone who is Rapid Metabolizer for CYP2C19 with regards to taking voriconazole?	Initiate therapy with recommended standard of care dosing. Use therapeutic drug monitoring to titrate dose to therapeutic trough concentrations.
voriconazole	CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer for CYP2C19 with regards to taking voriconazole?	Initiate therapy with recommended standard of care dosing
voriconazole	CYP2C19	What would be the clinical guidance for someone who is Likely Intermediate Metabolizer for CYP2C19 with regards to taking voriconazole?	Initiate therapy with recommended standard of care dosing
voriconazole	CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer for CYP2C19 with regards to taking voriconazole?	Initiate therapy with recommended standard of care dosing
voriconazole	CYP2C19	What would be the clinical guidance for someone who is Likely Poor Metabolizer for CYP2C19 with regards to taking voriconazole?	Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include liposomal amphotericin B and posaconazole. In the event that voriconazole is considered to be the most appropriate agent, based on clinical advice, for a patient with poor metabolizer genotype, voriconazole should be administered at a preferably lower than standard dosage with careful therapeutic drug monitoring.
voriconazole	CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer for CYP2C19 with regards to taking voriconazole?	Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include liposomal amphotericin B and posaconazole. In the event that voriconazole is considered to be the most appropriate agent, based on clinical advice, for a patient with poor metabolizer genotype, voriconazole should be administered at a preferably lower than standard dosage with careful therapeutic drug monitoring.
voriconazole	CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2C19 with regards to taking voriconazole?	Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include isavuconazole, liposomal amphotericin B, and posaconazole.
voriconazole	CYP2C19	What would be the clinical guidance for someone who is Rapid Metabolizer for CYP2C19 with regards to taking voriconazole?	Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include isavuconazole, liposomal amphotericin B, and posaconazole.
voriconazole	CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer for CYP2C19 with regards to taking voriconazole?	Initiate therapy with recommended standard of care dosing
voriconazole	CYP2C19	What would be the clinical guidance for someone who is Likely Intermediate Metabolizer for CYP2C19 with regards to taking voriconazole?	Initiate therapy with recommended standard of care dosing
voriconazole	CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer for CYP2C19 with regards to taking voriconazole?	Initiate therapy with recommended standard of care dosing
voriconazole	CYP2C19	What would be the clinical guidance for someone who is Likely Poor Metabolizer for CYP2C19 with regards to taking voriconazole?	Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include isavuconazole, liposomal amphotericin B, and posaconazole. In the event that voriconazole is considered to be the most appropriate agent, based on clinical advice, for a patient with poor metabolizer genotype, voriconazole should be administered at a preferably lower than standard dosage with careful therapeutic drug monitoring.
voriconazole	CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer for CYP2C19 with regards to taking voriconazole?	Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include isavuconazole, liposomal amphotericin B, and posaconazole. In the event that voriconazole is considered to be the most appropriate agent, based on clinical advice, for a patient with poor metabolizer genotype, voriconazole should be administered at a preferably lower than standard dosage with careful therapeutic drug monitoring.
voriconazole	CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2C19 with regards to taking voriconazole?	No recommendation
vortioxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 with regards to taking vortioxetine?	Select alternative drug not predominantly metabolized by CYP2D6. If vortioxetine use is warranted, initiate therapy at standard starting dose and titrate to maintenance dose based on efficacy and side effects. Increasing the target maintenance dose by 50% or more may be needed for efficacy.
vortioxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 with regards to taking vortioxetine?	Select alternative drug not predominantly metabolized by CYP2D6. If vortioxetine use is warranted, initiate therapy at standard starting dose and titrate to maintenance dose based on efficacy and side effects. Increasing the target maintenance dose by 50% or more may be needed for efficacy.
vortioxetine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 with regards to taking vortioxetine?	Initiate therapy with recommended starting dose.
vortioxetine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 with regards to taking vortioxetine?	Initiate therapy with recommended starting dose.
vortioxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 with regards to taking vortioxetine?	Select alternative drug not predominantly metabolized by CYP2D6. If vortioxetine use is warranted, initiate therapy at standard starting dose and titrate to maintenance dose based on efficacy and side effects. Increasing the target maintenance dose by 50% or more may be needed for efficacy.
vortioxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 with regards to taking vortioxetine?	Select alternative drug not predominantly metabolized by CYP2D6. If vortioxetine use is warranted, initiate therapy at standard starting dose and titrate to maintenance dose based on efficacy and side effects. Increasing the target maintenance dose by 50% or more may be needed for efficacy.
vortioxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 with regards to taking vortioxetine?	Select alternative drug not predominantly metabolized by CYP2D6. If vortioxetine use is warranted, initiate therapy at standard starting dose and titrate to maintenance dose based on efficacy and side effects. Increasing the target maintenance dose by 50% or more may be needed for efficacy.
vortioxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 with regards to taking vortioxetine?	Select alternative drug not predominantly metabolized by CYP2D6. If vortioxetine use is warranted, initiate therapy at standard starting dose and titrate to maintenance dose based on efficacy and side effects. Increasing the target maintenance dose by 50% or more may be needed for efficacy.
vortioxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 with regards to taking vortioxetine?	Select alternative drug not predominantly metabolized by CYP2D6. If vortioxetine use is warranted, initiate therapy at standard starting dose and titrate to maintenance dose based on efficacy and side effects. Increasing the target maintenance dose by 50% or more may be needed for efficacy.
vortioxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 with regards to taking vortioxetine?	Select alternative drug not predominantly metabolized by CYP2D6. If vortioxetine use is warranted, initiate therapy at standard starting dose and titrate to maintenance dose based on efficacy and side effects. Increasing the target maintenance dose by 50% or more may be needed for efficacy.
vortioxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 with regards to taking vortioxetine?	Select alternative drug not predominantly metabolized by CYP2D6. If vortioxetine use is warranted, initiate therapy at standard starting dose and titrate to maintenance dose based on efficacy and side effects. Increasing the target maintenance dose by 50% or more may be needed for efficacy.
vortioxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 with regards to taking vortioxetine?	Select alternative drug not predominantly metabolized by CYP2D6. If vortioxetine use is warranted, initiate therapy at standard starting dose and titrate to maintenance dose based on efficacy and side effects. Increasing the target maintenance dose by 50% or more may be needed for efficacy.
vortioxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 with regards to taking vortioxetine?	Select alternative drug not predominantly metabolized by CYP2D6. If vortioxetine use is warranted, initiate therapy at standard starting dose and titrate to maintenance dose based on efficacy and side effects. Increasing the target maintenance dose by 50% or more may be needed for efficacy.
vortioxetine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 with regards to taking vortioxetine?	Initiate therapy with recommended starting dose.
vortioxetine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 with regards to taking vortioxetine?	Initiate therapy with recommended starting dose.
vortioxetine	CYP2D6	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 with regards to taking vortioxetine?	Initiate 50% of starting dose (e.g., 5 mg) and titrate to the maximum recommended dose of 10 mg or consider a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2D6.
vortioxetine	CYP2D6	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 with regards to taking vortioxetine?	No recommendation
